WO2011022440A2 - Heat shock protein binding compounds, compositions, and methods for making and using same - Google Patents
Heat shock protein binding compounds, compositions, and methods for making and using same Download PDFInfo
- Publication number
- WO2011022440A2 WO2011022440A2 PCT/US2010/045817 US2010045817W WO2011022440A2 WO 2011022440 A2 WO2011022440 A2 WO 2011022440A2 US 2010045817 W US2010045817 W US 2010045817W WO 2011022440 A2 WO2011022440 A2 WO 2011022440A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- group
- saturated
- amino
- substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 205
- 238000000034 method Methods 0.000 title claims abstract description 59
- 230000027455 binding Effects 0.000 title claims description 50
- 238000009739 binding Methods 0.000 title claims description 50
- 239000000203 mixture Substances 0.000 title description 52
- 102000002812 Heat-Shock Proteins Human genes 0.000 title description 6
- 108010004889 Heat-Shock Proteins Proteins 0.000 title description 6
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 claims abstract description 115
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 71
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 52
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 50
- 150000003839 salts Chemical class 0.000 claims abstract description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 39
- 108010036652 HSC70 Heat-Shock Proteins Proteins 0.000 claims abstract description 20
- 102000012215 HSC70 Heat-Shock Proteins Human genes 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 238000012544 monitoring process Methods 0.000 claims abstract 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 317
- 229920006395 saturated elastomer Polymers 0.000 claims description 267
- 125000000217 alkyl group Chemical group 0.000 claims description 232
- 125000003118 aryl group Chemical group 0.000 claims description 204
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 174
- 125000003282 alkyl amino group Chemical group 0.000 claims description 172
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 171
- 125000004986 diarylamino group Chemical group 0.000 claims description 171
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 167
- 125000001769 aryl amino group Chemical group 0.000 claims description 165
- 125000000623 heterocyclic group Chemical group 0.000 claims description 156
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 155
- 229910052739 hydrogen Inorganic materials 0.000 claims description 150
- 210000004027 cell Anatomy 0.000 claims description 147
- 229910052736 halogen Inorganic materials 0.000 claims description 146
- 150000002367 halogens Chemical class 0.000 claims description 146
- 239000001257 hydrogen Substances 0.000 claims description 140
- 125000003342 alkenyl group Chemical group 0.000 claims description 137
- 125000004442 acylamino group Chemical group 0.000 claims description 135
- 125000003368 amide group Chemical group 0.000 claims description 135
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 135
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 134
- 125000000304 alkynyl group Chemical group 0.000 claims description 131
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 127
- 125000004104 aryloxy group Chemical group 0.000 claims description 127
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 127
- -1 alkylamido Chemical group 0.000 claims description 106
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 106
- 125000005422 alkyl sulfonamido group Chemical group 0.000 claims description 95
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 94
- 125000004001 thioalkyl group Chemical group 0.000 claims description 88
- 235000018102 proteins Nutrition 0.000 claims description 47
- 230000000694 effects Effects 0.000 claims description 44
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims description 42
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 claims description 42
- 201000011510 cancer Diseases 0.000 claims description 42
- 229910052760 oxygen Inorganic materials 0.000 claims description 41
- 239000003112 inhibitor Substances 0.000 claims description 27
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 25
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 25
- 206010006187 Breast cancer Diseases 0.000 claims description 20
- 208000026310 Breast neoplasm Diseases 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 229910052717 sulfur Inorganic materials 0.000 claims description 20
- 125000000539 amino acid group Chemical group 0.000 claims description 18
- 125000002837 carbocyclic group Chemical group 0.000 claims description 18
- 230000002062 proliferating effect Effects 0.000 claims description 18
- 239000003446 ligand Substances 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 230000006907 apoptotic process Effects 0.000 claims description 15
- 238000003556 assay Methods 0.000 claims description 15
- 230000015556 catabolic process Effects 0.000 claims description 15
- 238000006731 degradation reaction Methods 0.000 claims description 15
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 14
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 14
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000002252 acyl group Chemical group 0.000 claims description 12
- 230000008856 allosteric binding Effects 0.000 claims description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims description 8
- 238000003776 cleavage reaction Methods 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 8
- 230000007017 scission Effects 0.000 claims description 8
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 8
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 claims description 7
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 claims description 7
- 235000001014 amino acid Nutrition 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 230000001640 apoptogenic effect Effects 0.000 claims description 7
- 230000010261 cell growth Effects 0.000 claims description 7
- 230000009036 growth inhibition Effects 0.000 claims description 7
- 230000002779 inactivation Effects 0.000 claims description 7
- 108020001756 ligand binding domains Proteins 0.000 claims description 7
- 125000004193 piperazinyl group Chemical group 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 102000011727 Caspases Human genes 0.000 claims description 6
- 108010076667 Caspases Proteins 0.000 claims description 6
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 6
- 238000013500 data storage Methods 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 238000002875 fluorescence polarization Methods 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 claims description 5
- 230000009286 beneficial effect Effects 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 5
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 4
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 4
- 125000005250 alkyl acrylate group Chemical group 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 230000002860 competitive effect Effects 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 4
- 230000003936 working memory Effects 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 230000003190 augmentative effect Effects 0.000 claims description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000011232 storage material Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 36
- 239000012472 biological sample Substances 0.000 claims 4
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims 2
- 230000017066 negative regulation of growth Effects 0.000 claims 2
- LBJCUDZMNPAWPX-UHFFFAOYSA-N 2-amino-n-[3-[2-(4-methylpiperazin-1-yl)-4-phenylmethoxypyrimidin-5-yl]sulfanylphenyl]acetamide Chemical compound C1CN(C)CCN1C(N=C1OCC=2C=CC=CC=2)=NC=C1SC1=CC=CC(NC(=O)CN)=C1 LBJCUDZMNPAWPX-UHFFFAOYSA-N 0.000 claims 1
- RCQAEBYGVAKXIV-UHFFFAOYSA-N 2-amino-n-[3-[4-[(2-aminophenyl)methoxy]-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanylphenyl]acetamide Chemical compound C1CN(C)CCN1C(N=C1OCC=2C(=CC=CC=2)N)=NC=C1SC1=CC=CC(NC(=O)CN)=C1 RCQAEBYGVAKXIV-UHFFFAOYSA-N 0.000 claims 1
- XPLNHOQLTBFIEV-UHFFFAOYSA-N 2-amino-n-[3-[4-[(3,5-difluorophenyl)methoxy]-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanylphenyl]acetamide Chemical compound C1CN(C)CCN1C(N=C1OCC=2C=C(F)C=C(F)C=2)=NC=C1SC1=CC=CC(NC(=O)CN)=C1 XPLNHOQLTBFIEV-UHFFFAOYSA-N 0.000 claims 1
- POHPIHISICFSPX-UHFFFAOYSA-N 2-amino-n-[3-[4-[(3-aminophenyl)methoxy]-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanylphenyl]acetamide Chemical compound C1CN(C)CCN1C(N=C1OCC=2C=C(N)C=CC=2)=NC=C1SC1=CC=CC(NC(=O)CN)=C1 POHPIHISICFSPX-UHFFFAOYSA-N 0.000 claims 1
- VPXOPMWNCDOOHY-UHFFFAOYSA-N 2-amino-n-[3-[4-[(4-chlorophenyl)methoxy]-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanylphenyl]acetamide Chemical compound C1CN(C)CCN1C(N=C1OCC=2C=CC(Cl)=CC=2)=NC=C1SC1=CC=CC(NC(=O)CN)=C1 VPXOPMWNCDOOHY-UHFFFAOYSA-N 0.000 claims 1
- FURGBIZIANNWLU-UHFFFAOYSA-N 2-amino-n-[3-[4-[difluoro(phenyl)methoxy]-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanylphenyl]acetamide Chemical compound C1CN(C)CCN1C(N=C1OC(F)(F)C=2C=CC=CC=2)=NC=C1SC1=CC=CC(NC(=O)CN)=C1 FURGBIZIANNWLU-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000001037 lung lymphoma Diseases 0.000 claims 1
- OFOBBRIOXWIASO-UHFFFAOYSA-N n-[2-[4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanylpyrimidin-4-yl]prop-2-enamide Chemical compound COC1=NC(N2CCN(C)CC2)=NC(OC)=C1SC1=NC=CC(NC(=O)C=C)=N1 OFOBBRIOXWIASO-UHFFFAOYSA-N 0.000 claims 1
- SXCYNWXZUZUHKI-UHFFFAOYSA-N n-[3-[2-(4-methylpiperazin-1-yl)-4-phenylmethoxypyrimidin-5-yl]sulfanylphenyl]acetamide Chemical compound C1CN(C)CCN1C(N=C1OCC=2C=CC=CC=2)=NC=C1SC1=CC=CC(NC(C)=O)=C1 SXCYNWXZUZUHKI-UHFFFAOYSA-N 0.000 claims 1
- DNCACTLFFFYPLO-UHFFFAOYSA-N n-[3-[2-(4-methylpiperazin-1-yl)-4-phenylmethoxypyrimidin-5-yl]sulfanylphenyl]benzamide Chemical compound C1CN(C)CCN1C(N=C1OCC=2C=CC=CC=2)=NC=C1SC1=CC=CC(NC(=O)C=2C=CC=CC=2)=C1 DNCACTLFFFYPLO-UHFFFAOYSA-N 0.000 claims 1
- NVOGKZHADXJLOK-UHFFFAOYSA-N n-[3-[2-(4-methylpiperazin-1-yl)-4-phenylmethoxypyrimidin-5-yl]sulfanylphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(N=C1OCC=2C=CC=CC=2)=NC=C1SC1=CC=CC(NC(=O)C=C)=C1 NVOGKZHADXJLOK-UHFFFAOYSA-N 0.000 claims 1
- XTDMWIIDNJIEBM-UHFFFAOYSA-N n-[6-amino-2-[2-(4-methylpiperazin-1-yl)-4-phenylmethoxypyrimidin-5-yl]sulfanylpyrimidin-4-yl]prop-2-enamide Chemical compound C1CN(C)CCN1C(N=C1OCC=2C=CC=CC=2)=NC=C1SC1=NC(N)=CC(NC(=O)C=C)=N1 XTDMWIIDNJIEBM-UHFFFAOYSA-N 0.000 claims 1
- YBBRZWICSZOVDL-UHFFFAOYSA-N n-[6-amino-2-[4,6-diethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanylpyrimidin-4-yl]prop-2-enamide Chemical compound CCOC1=NC(N2CCN(C)CC2)=NC(OCC)=C1SC1=NC(N)=CC(NC(=O)C=C)=N1 YBBRZWICSZOVDL-UHFFFAOYSA-N 0.000 claims 1
- ZYAVZIQPWICPQI-UHFFFAOYSA-N n-[6-amino-2-[4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanylpyrimidin-4-yl]prop-2-enamide Chemical compound COC1=NC(N2CCN(C)CC2)=NC(OC)=C1SC1=NC(N)=CC(NC(=O)C=C)=N1 ZYAVZIQPWICPQI-UHFFFAOYSA-N 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 abstract description 9
- 230000035939 shock Effects 0.000 abstract description 5
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 abstract description 4
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 abstract description 4
- 238000011319 anticancer therapy Methods 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 107
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 104
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 56
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 50
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 45
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 44
- 230000002829 reductive effect Effects 0.000 description 44
- 239000011324 bead Substances 0.000 description 41
- 239000002904 solvent Substances 0.000 description 38
- 238000005160 1H NMR spectroscopy Methods 0.000 description 37
- 125000005647 linker group Chemical group 0.000 description 37
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 34
- 230000005764 inhibitory process Effects 0.000 description 33
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 31
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 30
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 30
- 238000004440 column chromatography Methods 0.000 description 28
- 238000001262 western blot Methods 0.000 description 28
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 23
- 238000004809 thin layer chromatography Methods 0.000 description 23
- 102000043276 Oncogene Human genes 0.000 description 22
- 208000035475 disorder Diseases 0.000 description 22
- 239000000284 extract Substances 0.000 description 22
- 108091008819 oncoproteins Proteins 0.000 description 22
- 239000003981 vehicle Substances 0.000 description 19
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 17
- 235000019439 ethyl acetate Nutrition 0.000 description 17
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- 108010090804 Streptavidin Proteins 0.000 description 14
- 125000001424 substituent group Chemical group 0.000 description 14
- 230000006870 function Effects 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 235000000638 D-biotin Nutrition 0.000 description 12
- 239000011665 D-biotin Substances 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 12
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 238000006722 reduction reaction Methods 0.000 description 11
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 10
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 10
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 10
- 239000013543 active substance Substances 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 150000003384 small molecules Chemical group 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 9
- ZSBDPRIWBYHIAF-UHFFFAOYSA-N N-acetyl-acetamide Natural products CC(=O)NC(C)=O ZSBDPRIWBYHIAF-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000003281 allosteric effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000006882 induction of apoptosis Effects 0.000 description 8
- 230000036210 malignancy Effects 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 102000000521 Immunophilins Human genes 0.000 description 7
- 108010016648 Immunophilins Proteins 0.000 description 7
- 102000007474 Multiprotein Complexes Human genes 0.000 description 7
- 108010085220 Multiprotein Complexes Proteins 0.000 description 7
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 7
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000003211 malignant effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- QCAWOHUJKPKOMD-UHFFFAOYSA-N 4,6-diamino-1h-pyrimidine-2-thione Chemical compound NC1=CC(N)=NC(S)=N1 QCAWOHUJKPKOMD-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 108010006519 Molecular Chaperones Proteins 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- IYRGXJIJGHOCFS-UHFFFAOYSA-N neocuproine Chemical compound C1=C(C)N=C2C3=NC(C)=CC=C3C=CC2=C1 IYRGXJIJGHOCFS-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 description 5
- 102000004447 HSP40 Heat-Shock Proteins Human genes 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- OJHAHQJRQIOCFK-UHFFFAOYSA-N azane;chloroform;methanol Chemical compound N.OC.ClC(Cl)Cl OJHAHQJRQIOCFK-UHFFFAOYSA-N 0.000 description 5
- HYTACLVSJIFYBY-UHFFFAOYSA-N azane;dichloromethane;methanol Chemical compound N.OC.ClCCl HYTACLVSJIFYBY-UHFFFAOYSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 101710128979 23 kDa piroplasm membrane protein Proteins 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 102000005431 Molecular Chaperones Human genes 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 101710177166 Phosphoprotein Proteins 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 102100028642 Prostaglandin E synthase 3 Human genes 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 101710094326 Ras-related protein R-Ras Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 101710157927 Translationally-controlled tumor protein Proteins 0.000 description 4
- 101710175870 Translationally-controlled tumor protein homolog Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 4
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 230000006369 cell cycle progression Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 3
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 3
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000009388 chemical precipitation Methods 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000001687 destabilization Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 230000002246 oncogenic effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- KYUTTZLLGAWFAP-UHFFFAOYSA-N 2-pyrimidin-5-ylsulfanylpyrimidine Chemical group N=1C=CC=NC=1SC1=CN=CN=C1 KYUTTZLLGAWFAP-UHFFFAOYSA-N 0.000 description 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 101150099575 CDC37 gene Proteins 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 102100029855 Caspase-3 Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101150101832 HSPA9 gene Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- 102000001788 Proto-Oncogene Proteins c-raf Human genes 0.000 description 2
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 230000001876 chaperonelike Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 150000001924 cycloalkanes Chemical class 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000004980 dosimetry Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012145 high-salt buffer Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000010309 neoplastic transformation Effects 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- REEZZSHJLXOIHL-UHFFFAOYSA-N octanoyl chloride Chemical compound CCCCCCCC(Cl)=O REEZZSHJLXOIHL-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000004650 oncogenic pathway Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000006920 protein precipitation Effects 0.000 description 2
- 230000004063 proteosomal degradation Effects 0.000 description 2
- MISVBCMQSJUHMH-UHFFFAOYSA-N pyrimidine-4,6-diamine Chemical compound NC1=CC(N)=NC=N1 MISVBCMQSJUHMH-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- SUPVGFZUWFMATN-UHFFFAOYSA-N zelavespib Chemical compound N1=CN=C2N(CCCNC(C)C)C(SC=3C(=CC=4OCOC=4C=3)I)=NC2=C1N SUPVGFZUWFMATN-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- KWMLJOLKUYYJFJ-GASJEMHNSA-N (2xi)-D-gluco-heptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C(O)=O KWMLJOLKUYYJFJ-GASJEMHNSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- KVGZZAHHUNAVKZ-UHFFFAOYSA-N 1,4-Dioxin Chemical compound O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 description 1
- OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical compound CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical compound CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- FGYADSCZTQOAFK-UHFFFAOYSA-N 1-methylbenzimidazole Chemical compound C1=CC=C2N(C)C=NC2=C1 FGYADSCZTQOAFK-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- OMAFFHIGWTVZOH-UHFFFAOYSA-N 1-methyltetrazole Chemical compound CN1C=NN=N1 OMAFFHIGWTVZOH-UHFFFAOYSA-N 0.000 description 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- KLICVZUEGODMNH-UHFFFAOYSA-N 1H-imidazole 1,2-oxazole 1,3-oxazole 1H-pyrazole 1,2-thiazole 1,3-thiazole Chemical compound S1N=CC=C1.S1C=NC=C1.O1N=CC=C1.O1C=NC=C1.N1C=NC=C1.N1N=CC=C1 KLICVZUEGODMNH-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- UXFWTIGUWHJKDD-UHFFFAOYSA-N 2-(4-bromobutyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCCBr)C(=O)C2=C1 UXFWTIGUWHJKDD-UHFFFAOYSA-N 0.000 description 1
- QAFDFEXCGOCOGG-UHFFFAOYSA-N 2-(cyanoamino)-2-oxoacetic acid Chemical compound OC(=O)C(=O)NC#N QAFDFEXCGOCOGG-UHFFFAOYSA-N 0.000 description 1
- DVXGFXLTGOOZQH-UHFFFAOYSA-N 2-[2-[2-[2-[6-methoxy-2-(4-methylpiperazin-1-yl)pyrimidin-4-yl]oxyethoxy]ethoxy]ethoxy]ethanol Chemical compound COC1=CC(OCCOCCOCCOCCO)=NC(N2CCN(C)CC2)=N1 DVXGFXLTGOOZQH-UHFFFAOYSA-N 0.000 description 1
- AZOMAPVTQSPORF-UHFFFAOYSA-N 2-[2-[bis[(4-methoxyphenyl)methyl]amino]-4,6-dimethoxypyrimidin-5-yl]sulfanylpyrimidine-4,6-diamine Chemical compound C1=CC(OC)=CC=C1CN(C=1N=C(OC)C(SC=2N=C(N)C=C(N)N=2)=C(OC)N=1)CC1=CC=C(OC)C=C1 AZOMAPVTQSPORF-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- QMEQBOSUJUOXMX-UHFFFAOYSA-N 2h-oxadiazine Chemical compound N1OC=CC=N1 QMEQBOSUJUOXMX-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- UNTNRNUQVKDIPV-UHFFFAOYSA-N 3h-dithiazole Chemical compound N1SSC=C1 UNTNRNUQVKDIPV-UHFFFAOYSA-N 0.000 description 1
- KWIVRAVCZJXOQC-UHFFFAOYSA-N 3h-oxathiazole Chemical compound N1SOC=C1 KWIVRAVCZJXOQC-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- JPZOAVGMSDSWSW-UHFFFAOYSA-N 4,6-dichloropyrimidin-2-amine Chemical compound NC1=NC(Cl)=CC(Cl)=N1 JPZOAVGMSDSWSW-UHFFFAOYSA-N 0.000 description 1
- LVFRCHIUUKWBLR-UHFFFAOYSA-N 4,6-dimethoxypyrimidin-2-amine Chemical compound COC1=CC(OC)=NC(N)=N1 LVFRCHIUUKWBLR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- VFEYBTFCBZMBAU-UHFFFAOYSA-N 4-chloro-6-methoxypyrimidin-2-amine Chemical compound COC1=CC(Cl)=NC(N)=N1 VFEYBTFCBZMBAU-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- FVYJDNDIAWXVSK-UHFFFAOYSA-N COC1=NC(N2CCN(CCCCNC(O)=O)CC2)=NC(OC)=C1SC1=NC(N)=CC(N)=N1 Chemical compound COC1=NC(N2CCN(CCCCNC(O)=O)CC2)=NC(OC)=C1SC1=NC(N)=CC(N)=N1 FVYJDNDIAWXVSK-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102100022207 E3 ubiquitin-protein ligase parkin Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001095089 Homo sapiens PML-RARA-regulated adapter molecule 1 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- UQFQONCQIQEYPJ-UHFFFAOYSA-N N-methylpyrazole Chemical compound CN1C=CC=N1 UQFQONCQIQEYPJ-UHFFFAOYSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 1
- 102100037019 PML-RARA-regulated adapter molecule 1 Human genes 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 1
- JZFICWYCTCCINF-UHFFFAOYSA-N Thiadiazin Chemical compound S=C1SC(C)NC(C)N1CCN1C(=S)SC(C)NC1C JZFICWYCTCCINF-UHFFFAOYSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 125000004062 acenaphthenyl group Chemical group C1(CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000003349 alamar blue assay Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000006323 alkenyl amino group Chemical group 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000009876 antimalignant effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N beta-hydroxyethanesulfonic acid Natural products OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- SKKTUOZKZKCGTB-UHFFFAOYSA-N butyl carbamate Chemical compound CCCCOC(N)=O SKKTUOZKZKCGTB-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
- MNQDKWZEUULFPX-UHFFFAOYSA-M dithiazanine iodide Chemical compound [I-].S1C2=CC=CC=C2[N+](CC)=C1C=CC=CC=C1N(CC)C2=CC=CC=C2S1 MNQDKWZEUULFPX-UHFFFAOYSA-M 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- JOXWSDNHLSQKCC-UHFFFAOYSA-N ethenesulfonamide Chemical compound NS(=O)(=O)C=C JOXWSDNHLSQKCC-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000034725 extrinsic apoptotic signaling pathway Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000034727 intrinsic apoptotic signaling pathway Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 125000002463 lignoceryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000005741 malignant process Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- CDMJDESECCKWAX-UHFFFAOYSA-N n-[6-acetamido-2-(2-amino-4,6-dimethoxypyrimidin-5-yl)sulfanylpyrimidin-4-yl]acetamide Chemical compound COC1=NC(N)=NC(OC)=C1SC1=NC(NC(C)=O)=CC(NC(C)=O)=N1 CDMJDESECCKWAX-UHFFFAOYSA-N 0.000 description 1
- MBALKHXJZPESLC-UHFFFAOYSA-N n-[6-acetamido-2-[2-[bis[(4-methoxyphenyl)methyl]amino]-4,6-diethoxypyrimidin-5-yl]sulfanylpyrimidin-4-yl]acetamide Chemical compound CCOC1=NC(N(CC=2C=CC(OC)=CC=2)CC=2C=CC(OC)=CC=2)=NC(OCC)=C1SC1=NC(NC(C)=O)=CC(NC(C)=O)=N1 MBALKHXJZPESLC-UHFFFAOYSA-N 0.000 description 1
- WODPSWGZCWMLKK-UHFFFAOYSA-N n-[6-acetamido-2-[2-[bis[(4-methoxyphenyl)methyl]amino]-4,6-dimethoxypyrimidin-5-yl]sulfanylpyrimidin-4-yl]acetamide Chemical compound C1=CC(OC)=CC=C1CN(C=1N=C(OC)C(SC=2N=C(NC(C)=O)C=C(NC(C)=O)N=2)=C(OC)N=1)CC1=CC=C(OC)C=C1 WODPSWGZCWMLKK-UHFFFAOYSA-N 0.000 description 1
- FTCNNKAOOAINQJ-UHFFFAOYSA-N n-[6-amino-2-[2-[4-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]piperazin-1-yl]-4,6-dimethoxypyrimidin-5-yl]sulfanylpyrimidin-4-yl]prop-2-enamide Chemical compound COC1=NC(N2CCN(CCOCCOCCOCCO)CC2)=NC(OC)=C1SC1=NC(N)=CC(NC(=O)C=C)=N1 FTCNNKAOOAINQJ-UHFFFAOYSA-N 0.000 description 1
- DNDTZOMLJOVLCL-UHFFFAOYSA-N n-[6-amino-2-[4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanylpyrimidin-4-yl]octanamide Chemical compound CCCCCCCC(=O)NC1=CC(N)=NC(SC=2C(=NC(=NC=2OC)N2CCN(C)CC2)OC)=N1 DNDTZOMLJOVLCL-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100001222 nononcogenic Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- LTHCSWBWNVGEFE-UHFFFAOYSA-N octanamide Chemical compound CCCCCCCC(N)=O LTHCSWBWNVGEFE-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- GMQOZFVOGGIFIX-UHFFFAOYSA-N oxathiazolidine Chemical compound C1COSN1 GMQOZFVOGGIFIX-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 238000003322 phosphorimaging Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HCJTYESURSHXNB-UHFFFAOYSA-N propynamide Chemical compound NC(=O)C#C HCJTYESURSHXNB-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000026938 proteasomal ubiquitin-dependent protein catabolic process Effects 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000003351 stiffener Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 108010051423 streptavidin-agarose Proteins 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- YGNGABUJMXJPIJ-UHFFFAOYSA-N thiatriazole Chemical compound C1=NN=NS1 YGNGABUJMXJPIJ-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000004953 trihalomethyl group Chemical group 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical compound CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000003041 virtual screening Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Definitions
- the present subject matter relates to a compound represented by the general formulae disclosed herein or a pharmacologically acceptable salt thereof; pharmaceutical compositions containing the compound; methods of making the compound; methods of using the compound for treating and/or preventing various malignancies or proliferation disorders; methods of using the compound to identify matter that treats and/or prevents various malignancies or proliferation disorders; methods of using the compound to identify biomarkers for the clinical development of matter to treat and/or prevent various malignancies or proliferation disorders; and methods of using the compound to identify its rational use in combination therapies.
- the present subject matter relates to a compound that is a small molecule modulator of heat shock protein 70 (Hsp70).
- Hsp70 heat shock protein 70
- the subject matter relates to a small molecule that occupies an allosteric pocket of Hsp70 located outside the nucleotide binding site of Hsp70 and to methods for identifying, characterizing, and using such small molecule
- HSPs heat shock proteins
- Hsp90 and Hsp70 proteins that act in an interconnected but also distinct fashion to regulate the malignant phenotype.
- Hsp90 maintains the transforming capacity of several onco-proteins, among which HER2, AKT, RAFl, IGF-IR, and HIF-I, function facilitated by Hsc70, the constitutive Hsp70, the inducible Hsp70 isoforms.
- Hsp90 inhibition the Hsp90-client onco-proteins become destabilized and are degraded by a proteasomal pathway (Fig. Ia).
- the transcription factor HSF-I is another Hsp90 client, and unlike onco-proteins, it becomes activated when Hsp90 is inhibited. HSF-I activation leads to an increase in Hsp70 levels, a feed-back response that limits the potency of Hsp90 inhibitors in certain tumors. Hsp70 in itself is a powerful anti- apoptotic molecule, suggesting that inhibition of both intrinsic and extrinsic apoptotic pathways by increased Hsp70 levels may be responsible for reducing the effect of Hsp90 inhibition. In addition to inhibiting apoptosis and assisting Hsp90, Hsp70 and its highly homologous cytosolic isoforms, serve many other overlapping chaperone functions and in some cases can substitute for each other.
- the Hsp90 multi-chaperone complex also called the Hsp90 super-chaperone machinery, has important roles in the development and progression of pathogenic cellular transformation through regulation of several malignancy driving and supporting client proteins.
- the activity of the Hsp90 multi-chaperone system is maintained and executed by a complex system of chaperones.
- the Hsp70s (constitutively expressed Hsc70 and the heat inducible Hsp70-l and Hsp70-6) participate in the preliminary steps, whereas Hsp90 participates in the later stages (Fig. Ia).
- Hsp70- regulators such as the Hsp70- regulators, Hsp40, Hspl lO, BAG and HIP; HSP-organizing protein (HOP), involved in the formation of the intermediate molecular chaperone complex where the client is passed from Hsp70 to Hsp90, and others such as p23, cdc37 and immunophilins, acting at the final or mature Hsp90 complex (Fig. Ia).
- Hsp90 machinery through agents that act by direct binding to the regulatory ATPase pocket of Hsp90, such as geldanamycin (GM) and the PUderivatives PU24FC1 and PU-H71 (Fig.
- HSF-I activation does not require Hsp70, unlike the onco-protein clients of the Hsp90 machinery.
- the present subject matter provides compounds and methods to differentiate the two functions of the Hsp90 molecular machinery, namely regulation of onco-proteins and suppression of HSF-I, by specifically modulating the Hsp70 chaperones.
- the compounds described herein may be useful for modulating cell growth, such as, for example, inhibiting malignant cells and/or increasing cytotoxicity against cancer cells, hi another embodiment, the compounds described herein may function as heat shock protein 70 (Hsp70) modulators.
- Hsp70 heat shock protein 70
- the compounds described herein can disrupt the formation of Hsp90 machinery/onco-protein complexes, leading to proteasomal degradation of several onco-proteins, without disrupting or degrading non-oncogenic kinases, hi further embodiments, the anti-cancer effects of the compounds described herein may comprise, for example, inhibition of proliferation, transformation-specific block of the cell cycle, induction of apoptosis, or reduction of invasiveness.
- compositions of matter that interact by either a irreversible or reversible binding mode.
- these compounds interact with Hsp70.
- they interact with a herein described allosteric site on Hsp70.
- a homology model of human Hsp70 is presented.
- the homology model is used to rationally design compounds that modulate the activity of mammalian Hsp70. This homology model will be useful for the discovery of compounds of the present subject matter by methods including but not limited to rational drug design and virtual screening.
- an allosteric pocket located outside the nucleotide binding site of Hsp70 and Hsc70 is presented. No natural or synthetic small molecule ligands are known for this pocket. In yet other embodiments, it is presented that occupying mis pocKet witn a small molecule ligand will result in, for example, inhibition of proliferation, transformation- specific block of the cell cycle, induction of apoptosis, or reduction of invasiveness. This pocket will be useful for the discovery of compounds of the present subject matter.
- a candidate compound can be computationally provided by several methods.
- Examples of such methods include assembling molecular fragments into a candidate compounds, designing a candidate compound de novo, modifying a compound known to bind to the site, including the composition described herein, to form a candidate compound, and not lastly, by screening a database for a candidate compound.
- a cavity in the Hsp70 protein that has no known naturally occurring or synthetically created ligand, when occupied by a compound of the present subject matter as described herein, results in inhibition of malignant cell growth, inhibition of aberrant cell cycle progression, degradation and inhibition of several onco-proteins, induction of apoptosis and reduction in the invasive potential of cancer cells at doses that are not toxic to normal cells.
- occupancy of this yet unexplored pocket by other small molecule ligands will lead to all or a subset of the following effects, but is not limited to: inhibition of malignant cell growth, inhibition of aberrant cell cycle progression, degradation and inhibition of several onco-proteins, induction of apoptosis and reduction in the invasive potential of cancer cells at doses that are not toxic to normal cells.
- Hsp70 and Hsc70 While targeting one HSP at a time has its clear therapeutic significance, embodiments presented here show that by simultaneously inhibiting Hsp70 and Hsc70, one could reap the beneficial effects of Hsp90 inhibition, namely depletion of tumors of onco-proteins driving malignant processes, such as proliferation, survival and metastasis, and the apoptotic effects of Hsp70 inhibition.
- one embodiment describes a novel cancer targeting strategy by inhibition of an allosteric pocket located outside the nucleotide binding site of Hsp70 and Hsc70.
- a strategy comprising one or more of several methods to evaluate the ability of a candidate compound to act with the substantial and wide-ranging beneficial consequences in cancer cells of the herein described compounds of the present subject matter.
- the strategy includes testing for a herein described phenotypic outcome in select cancer cells, performing a competitive tiuorescence polarization assay to test for Hsp90 and Hsp70 binding as described herein, and evaluating computationally the structural fit of the candidate compound into the herein mentioned pocket.
- the phenotypic test includes but is not limited to testing for growth inhibition in a large panel of cancer cells, HER2 and Raf-1 degradation in HER2+ SKBr3 breast cancer cells, FLT3 and p- STAT5 inactivation in MOLM-13 AML cells, p-STAT3 and ⁇ -PDKl inactivation in MDA-MB- 468 triple negative breast cancer cells, mutant AR degradation in LNCaP prostate cancer cells, PARP cleavage in a large panel of cancel cells, caspase 3,7 activation in MOLM-13 cells, augmenting the apoptotic effect of interferon and TNF in breast cancer cells, and lack of Hsp70 induction in a large panel of cancer cells.
- the Hsp70 and Hsp90 competitive assays test competitive binding of candidate compounds to HSP expressed in cancer cells.
- Hsp70 in complexes with its onco-client protein cargo.
- a solid-support immobilized version of a compound described herein therefore confers the unprecedented possibility to investigate the cancer Hsp70 interactome in an endogenous cellular environment.
- compounds of the herein described subject matter may also be derivatized to form biotin-containing compounds that can be attached onto streptavidin or avidin beads, or can be directly linked to a correspondingly functionalized resin, such as but not limited to agarose, sepharose and matrigel resin.
- the compounds described herein may be derivatized with a fluorescent dye, such as but not limited to Cy3B, FITC and BODiPY.
- a fluorescent dye such as but not limited to Cy3B, FITC and BODiPY.
- this compound may be used to screen for candidate compounds that interact with Hsp70 in a manner similar to compounds of the present subject matter described herein.
- the solid support immobilized compound described herein is used to identify that tumor-by-tumor components of oncogenically activated pathways are in complex with Hsp70. Addition of compositions described herein to specific cancer cells results in destabilization of these complexes, onco-protein degradation or inhibition, and cancer cell growth inhibition and death. These downstream events of tumor Hsp70 inhibition may be used to functionally monitor the effect of compounds of the present subject matter described herein.
- the method described herein thus provides effective analysis of functional molecular biomarkers associated with response to the described compounds of the present subject matter and to other therapy that acts by occupying the allosteric pocket described herein or that is identified through the assay described herein. It is proposed that these biomarkers are useful in the clinical development of compositions of matter described herein, of compositions of matter that occupy the pocket described herein or of compositions of matter that are identified by the assays described herein.
- Hsp90- machinery co-chaperones such as Hsp70, or HOP, HIP, p23, or Hsp40
- HSF-I Hsp90- machinery co-chaperones
- the compounds of the present subject matter might not, for example, activate HSF-I nor induce a protective feed-back heat shock response.
- the compounds disrupt the formation of Hsp90 machinery/onco-protein complexes without activating HSF-I and/or without inducing a protective feed-back heat shock response.
- pharmacologic administration of the compounds in some embodiments results in increased, but yet selective, cytotoxicity against cancer cells, due to apoptosis, for example.
- the biological consequence of pharmacologic inhibition of Hsp70 has been characterized in malignant cells by using the compounds of the present subject matter. It has been found that Hsp70 modulates dephosphorylation of the STATl tumor suppressor in breast cancer cells, a novel mechanism of inactivation of the STATl tumor suppressor, hi another embodiment of the present subject matter, the compounds described herein inhibit or inactivate Hsp70 acceleration of STATl dephosphorylation in breast cancer cells, thereby promoting tumor suppression via continued activity of the tumor suppressor STATl.
- STATl is a major effector of interferon-(IFN) ⁇ signaling.
- IFN ⁇ is a cytokine produced by T-cells and natural killer cells with an essential immune-stimulating function that provides defense against the development of tumors.
- compositions of matter presented herein augment the effect of IFN ⁇ and of another cytokine, TNF ⁇ and could allow immune responses to much more potently wipe out tumors.
- Hsp90 chaperoning cycle is a dynamic process in which client proteins are presented to Hsp90 in an intermediate complex containing Hsp70s, Hsp40, HIP and HOP.
- Hsp90 forms a mature complex, containing p23, p50/cdc37 and immunophilins (IP), which catalyzes the conformational maturation of Hsp90 client proteins.
- Hsp90-inhibitor drugs such as geldanamycin (GM) and the purine-scaffold derivatives PU-H71 and PU24FC1, bind to the N-terminal ATP-binding pocket of Hsp90 and inhibit ATP binding and hydrolysis, thereby locking Hsp90 in the intermediate complex.
- the client protein is subsequently ubiquitinated (possibly by an E3 ubiquitin ligase such as CHIP) and targeted to the proteasome for degradation.
- E3 ubiquitin ligase such as CHIP
- FIG. 1 Design of the YK-class Hsp70s interactors and the computational model of the YK5-Hsp70 complex, a) Putative binding sites of Hsp70 were predicted by SiteMap v2.2 program of Maestro 8.5 (Schrodinger L.L.C., NY). SiteMap was configured to return up to 5 probable sites ranked according to Site score and Draggability score. In this study all other parameters of SiteMap were set to default values. The presented structure is a homology model constructed using the human Hsp70 N-terminal domain (PDB ID: 1S3X), the E. coli DnaK (PDB ID: 2kho) and the human Hsp70 protein sequence.
- FIG. 3 Testing strategy for the discovery of YK5.
- a b) SKBr3 cells were treated for 24 h with the indicated concentrations of inhibitors and cells were lysed for western blot (WB) analysis, ⁇ -actin was used as loading control. The data are consistent with those obtained from multiple repeat experiments (n > 3).
- FIG. 4 YK5 interacts selectively with Hsp70 and Hsc70.
- K562 cells were treated with the indicated concentrations of YK55 for 6 h prior to lysing and precipitation of protein complexes on streptavidin beads (50 ⁇ l) for Ih at 4 0 C. Beads were washed with high-salt (1 M NaCl) buffer, proteins eluted by boiling in 2% SDS, separated on a denaturing gel and silver stained.
- BB70 Ab pull-downs were used to indicate the position of Hsp70s (BB70 IP; 2 ⁇ l).
- Hsp70 heavy chain
- SKBr3 cells were treated for 24 h with the indicated concentrations of YK5 and cells were lysed. Protein complexes were isolated through chemical precipitation by incubating the cell extract (500 ⁇ g) with YK55-beads (50 ⁇ l), eluted with 2%SDS, separated on a denaturing gel and visualized as indicated. YK55 beads were made by incubating YK55 (50 ⁇ M) with streptavidin beads (50 ⁇ l).
- HC heavy chain ⁇ left). Binding of protein complexes to YK55 beads was probed in SKBr3 cell extracts in which Hsp/c70 levels were reduced by BB70 Ab or IgG immunoprecipitation, respectively. Proteins were analyzed by WB (right).
- K562 cells were treated with YK55 or D-biotin (50 ⁇ M) for 6 h and lysed. Extracts (500 ⁇ g) were incubated for 1 h at 4°C with streptavidin (ST)-beads and pull-downs washed with high-salt buffer (IM NaCl). Proteins were eluted by boiling in buffer A or B, as described in Methods. Following separation on a denaturing gel, proteins were visualized by WB. The data are consistent with those obtained from multiple repeat experiments (n > 2). d) MALDI-reTOF- MS/MS analysis of YK55 binding to Hsp70s in cancer cells.
- K562 cells were treated for 4 h with 100 ⁇ M YK55 and lysed.
- YK55 treated cell extract 500 ⁇ g was incubated with streptavidin agarose beads for 1 h at 4°C. Beads were washed with high-salt buffer (1 M NaCl), proteins eluted by boiling in 2% SDS, separated on a denaturing gel and Coomassie stained. Gel-resolved proteins were digested with trypsin and peptides identified as indicated in Methods.
- Hsp90/Hsp70 interaction a) Refolding of denatured luciferase by Hsc70 and DJA2 at 30 0 C was measured for the indicated times in the presence of YK5 (100 ⁇ M) or vehicle (left), or at 60 min in the presence of indicated concentrations of YK5 (right), b) Hsc70 ATPase rates were measured for reactions at 30 0 C with the indicated combinations of Hsc70 and co-chaperones in the presence of vehicle (DMSO) or YK5 (100 ⁇ M). ADP production was monitored by thin layer chromatography separation of radiolabeled ADP from ATP and phosphorimaging analysis (lower). The data are consistent with those obtained from multiple repeat experiments (n > 2).
- YK5 disrupts the Hsp90/Hsp70/onco-client proxem complexes resuning in oncoprotein destabilization and subsequent degradation by the proteasome.
- FIG. 8 Structure-activity relationship in the YK-series. a) SKBr3 breast cancer cells were treated for 24 h with indicated concentrations of YK-derivatives and proteins analyzed by Western blot, b) Kasumi-1 cells were incubated with increasing concentrations of YK- derivatives and inhibition of cell growth was analyzed with the Alamar blue assay as indicated in Methods. Points, mean; bars, s.d.. Yaxis values below 0% represent cell death of the starting population, c) Streptavidin beads (50 ⁇ l) were incubated with the indicated concentrations of YK55, YK56 or D-biotin to immobilize the corresponding compounds on beads.
- Figure 9 Examples of the compounds of the present subject matter dose-dependently reduce the steady- state levels of HER2 and Raf-1 onco-kinases in the SKBr3 HER2 overexpressing breast cancer cells, and induce apoptosis as indicated by PARP cleavage. Cells were treated for 24h with the indicated concentrations of YKl 49 and YK5. Cells were lysed and proteins analyzed by western blotting, b) Examples of the compounds of the present subject matter inhibit the activity of the oncogenic STAT3 in the triple-negative breast cancer cells MDA-MB-468.
- Figure 10 (a) Examples of the compounds of the present subject matter dose-dependently reduce the steady-state levels of Raf-1 onco-kinase in the triple-negative breast cancer cells MDA-MB-468, and induce apoptosis as indicated by PARP cleavage. Examples of the compounds of the present subject matter dose-dependently reduce the steady-state levels of HER2 and Raf-1 onco-kinases in the SKBr3 HER2 overexpressing breast cancer cells, and induce apoptosis as indicated by PARP and caspase-3 cleavage. No associated induction of Hsp70 is observed.
- Example of the compounds of the present subject matter dose-dependently reduces the steady-state levels of FLT3 and p-STAT5 in the MOLM- 13 mutant FLT3 expressing acute myeloid leukemia cells.
- Cells were treated for 24h with the indicated concentrations of compounds or for the indicated times with the indicated concentration of compounds. Cells were lysed and proteins analyzed by western blotting,
- Examples of the compounds of the present subject matter dose-dependently induce apoptosis in the acute myeloid leukemia cells M0LM13. Cells were treated for 24h with the indicated concentration of compounds and the increase in caspase3,7 activity was measured and compared to only vehicle (DMSO) treated cells.
- DMSO vehicle
- Caspase- 3,7 activity was a measure of compound potency in cleaving the caspase substrate Z-DEVD- RIlO and releasing rhodamine.
- the percentage increase in apoptotic cells was calculated by comparing the fluorescence readings obtained from compounds with those obtained from vehicle (DMSO)-treated cells.
- FIG. 11 Examples of the compounds of the present subject matter reduce dose-dependently the steady-state levels of HER2 and Raf-1 oncokinases in the SKBr3 HER2 overexpressing breast cancer cells, and induce apoptosis as indicated by PARP cleavage. Cells were treated for 24h with the indicated concentrations of agent. Cells were lysed and proteins analyzed by western blotting, (b) Examples of the compounds of the present subject matter inhibit the activity of the oncogenic STAT3, reduce the steady- state levels of Raf-1 and induce apoptosis in the triple-negative breast cancer cells MDA-MB-468. Cells were treated for 24h with the indicated compounds or for the indicated times with the indicated concentrations oi me compounds, and proteins analyzed by western blot.
- Tumor volume (mm 3 ) was estimated from caliper measurements, (c) Cells were treated for 24 h with indicated concentrations of YK5. DNA content was analyzed by propidium iodide staining and flow cytometry (left), whereas proteins by western blotting (right), (d) Hsp70 client proteins isolated by YK55-beads from SKBr3 and MDA-MB-468 extracts (500 ⁇ g) were analyzed by western blotting.
- Control beads contain D-biotin (100 ⁇ M) attached, (e) MDA-MB- 231 breast cancer cells were treated for 24 h with YK5 (1 ⁇ M) and protein extracts were subjected to immunob lotting (upper) or pre-treated for 24 h with vehicle or YK5, and viable cells able to migrate through Matrigel over a 20 h period were quantified and data graphed (lower). Points, mean; bars, s.d. The data are consistent with those obtained from multiple repeat experiments (n > 3).
- YK5 has a higher apoptotic effect than Hsp90 inhibitors in select tumors
- FIG. 14 YK5 has a higher affinity for tumor Hsp70s and selectively kills cancer cells
- (a-c) Cells were treated with the indicated concentrations of inhibitors for the times presented, and metabolically viable cells by Alamar blue uptake as described in Methods (a).
- Molecular markers of apoptosis (PARP and caspase-3 cleavage) were analyzed in cells treated for 24 h with indicated concentrations of inhibitors, by western blotting (b, c). Morphology of cells treated for 24 h with vehicle or the indicated inhibitors was analyzed by light microscopy (c).
- Extracts 500 ⁇ g were incubated overnight with beads containing D-biotin (75 ⁇ M) or the indicated concentrations of YK55 added to 50 ⁇ l streptavidin beads.
- HS heat shocked
- SKBr3 200 ⁇ g
- MRC-5 400 ⁇ g extracts and recombinant human Hsp70 (2 ⁇ g) were incubated for 3 h with the indicated concentrations with YK5, followed by precipitation of Hsp70 complexes on YK55-beads (50 ⁇ M YK55 added to 50 ⁇ l streptavidin beads).
- Data obtained from three independent experiments were graphed (right). Points, mean; bars, s.d.
- Figure 15 A solid-support attached YK5, YK55-beads, isolates in a tumor-specific manner Hsp70 in complex with onco-proteins.
- Hsp70 complexes precipitated from indicated cell extracts (500 ⁇ g) with YK55- or D-biotin-beads (100 ⁇ M YK55 or D-biotin added to 50 ⁇ l streptavidin beads, respectively) were analyzed by WB.
- FIG. 16 Hsp70 competitive fluorescence polarization assay. Increasing concentrations of indicated inhibitors were added in triplicate to the assay plate and the Fluorescence Polarization (FP) assay was performed as indicated in Methods. The competitive effect was expressed as percentage of control and was calculated by dividing the millipolarization (mP; subtracting free cy3B-YK5) value from inhibitor wells by the average mP (subtracting free cy3B-YK5) from controls (cy3B-YK5 and cell lysate with vehicle DMSO) in each plate. Ligand binding was plotted against the logio inhibitor concentration, and EC 50 values were calculated using a nonlinear least-square curve-fitting program in Prism 4.0.
- YK5 identifies STATl and STAT3 as n ⁇ vti n ⁇ / w .ixivi «vmi 6 oncogenic products in breast cancer cells
- DMSO vehicle
- YK5 10 ⁇ M
- Example compositions of matter potently inhibit STAT3 in the triple-negative cells MDA-MB-468.
- Activated STAT3 is part of an important oncogenic pathway in triple-negative breast cancers.
- FIG. 18 YK5 uncovers a novel mechanism of inhibition of the pro-apoptotic effect of STATl tumor suppressor, (a) YK55 beads recognize Hsp70 in complex with p-STATl and STATl in MDA-MB-468 extracts (500 ⁇ g). (b) Binding of protein complexes to YK55 beads was probed in MDA-MB-468 cell extracts with Hsp/c70 levels reduced by BB70 Ab or IgG immunoprecipitation.
- MDA-MB-468 cells were treated 7 h with vehicle, IFN ⁇ lOO ng/ml), YK5 (10 ⁇ M), pretreated with YK5 for 2 h before IFN ⁇ stimulation or co-treated and cells were lysed for western blot analysis,
- FIG. 19 YK5 enhances the nuclear content of IFN ⁇ activated STATl and potentiates its binding to DNA.
- MDAMB-468 cells were treated with IFN ⁇ (100 ng/ml) or co- treated with IFN ⁇ (100 ng/ml) and YK5 (10 ⁇ M).
- Activated STATl (pTyr701), was determined by immunofluorescent microscopy with a secondary antibody conjugated with FITC. Nuclear staining was performed with DAPI.
- Activated STATl binding to STAT consensus binding site (5'-TTCCCGGAA-S') was determined by an ELISA-based assay.
- Activated STATl contained in lysates from untreated (white bar), treated with YK5 (light grey bar), IFN ⁇ (dark grey bars) or the combination of IFN ⁇ and YK5 (black bars) cells, and bound to the oligonucleotide, was detected through use of an anti-STATl antibody. Assays were performed in the absence or presence of 20 pmol of competitor oligonucleotide that contains either a wild-type or a mutated STAT consensus binding site using IFN ⁇ -treated cells (dark grey bars). Experiments were carried out in four replicates. Results are expressed as mean absorbance values (OD450nm) with SEM.
- FIG. 20 Treatment of primary AML cells with YK5.
- YK5 kills both blast and cancer stem cells but not normal cells. Cells were treated with increasing concentrations of YK5 for 24h.
- Open bars “Other” represent normal cells in the same patient (non-blast), Gray bars: Blasts (CD45 dim), red bars: leukemia stem cells (LSCs) (CD34+CD38-CD123+).
- CFU Coldy forming units
- Figure 21 Alignment of protein sequence of full length hHsp70 (SEQ ID NO:1)
- administer refers to any method which, in sound medical practice, delivers the composition to a subject in such a manner as to provide a therapeutic effect.
- derivative refers to any hydrate, solvate, salt, racemate, isomer, enantiomer, prodrug, metabolite, ester, or other analog or derivative of a particular chemical compound or molecule.
- derivative may also mean a modification to the disclosed compounds including, but not limited to, hydrolysis, reduction, or oxidation products of the disclosed compounds. Hydrolysis, reduction, and oxidation reactions are known in the art.
- modulating refers to the process of producing an effect on biological activity, function, health, or condition of an organism in which such biological activity, function, health, or condition is maintained, enhanced, diminished, or treated in a manner which is consistent with the general health and well-being of the organism.
- enhancing the biological activity, function, health, or condition of an organism refers to the process of augmenting, fortifying, strengthening, or improving.
- a therapeutically effective amount of the pharmaceutically active agent may, will, or is expected to cause a relief of symptoms. Effective amounts of the pharmaceutically active agent will vary with the particular condition or conditions being treated, the severity of the condition, the duration of the treatment, the specific components of the composition being used, and like factors.
- any substituent as used herein in defining formula (I) and ( F), means any substituent that may be replaced for hydrogen.
- the term “any substituent,” as used herein in defining formula (I) and ( V), is an optionally substituted straight or branched alkyl, alkenyl, or alkynyl group; an optionally substituted carbocyclic, heterocyclic, aryl, or heteroaryl group; halo; an optionally substituted C 2-22 acyl group; hydroxyl; nitro; cyano; aryloxy; alkoxy; halogenated alkoxy; alkenyloxy; hydroxyalkyl; amino; alkylamino; dialkylamino; cycloalkylamino; arylamino; diarylamino; acylamino; carbamyl; substituted or unsubstituted amido; alkylamido; alkylsulfonamido; sulfonamido
- any substituent refers to a substituent that comprises a label or marker group useful for identifying, tracking, and or isolating the compound.
- label groups and marker groups useful herein include, for example, fluorescent groups, biotin groups, avidin groups, and enzyme linker groups.
- alkyl refers to an optionally substituted linear, cyclic, or branched saturated hydrocarbon group, in which the atom attached to the remainder of the structure is a carbon atom.
- the alkyl group may have 1 to 24 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, octyl, decyl, tetradecyl, hexadecyl, eicosyl, tetracosyl and the like.
- Preferred "alkyl” groups herein contain 1 to 12 carbon atoms.
- “Lower alkyl” refers to an alkyl group of one to six, more preferably one to four, carbon atoms.
- the alkyl group may have substituents, for example halogen, hydroxy, alkoxy, amino, substituted and unsubstituted substituted and unsubstituted amido, sulfonamino, sulfonamido, sulphoxy, aryl, cyano, carboxy, carboxamide, acyl, nitro, tliio.
- alkenyl refers to an optionally substituted linear, cyclic, or orancneu unsaturated hydrocarbon group having a carbon-carbon double bond at one or more places, in which the atom attached to the remainder of the structure is a carbon atom.
- the alkenyl group may have 2-20 carbons, preferably 2-8 carbons.
- the linear alkenyl group includes, for example: a 1-alkenyl group such as an ethenyl group, 1-propenyl group, and 1-butenyl group; and a 2- alkenyl group such as a 2-butenyl group, and 2-pentenyl group.
- the alkenyl group may have substituents that are the same as for an alkyl group.
- alkynyl refers to an optionally substituted branched or unbranched unsaturated hydrocarbon group having a carbon-carbon triple bond at one or more places, in which the atom attached to the remainder of the structure is a carbon atom.
- the alynyl group may have 2-20 carbons, preferably 2-8 carbons. Examples include: a 1 -alkynyl group such as ethynyl group, 1-propynyl group, and 3, 3 -dimethyl- 1-butynyl group; and a 2-alkynyl group such as a 2-propynyl group, 2-butynyl group, and 3-phenyl-2-propynyl group.
- the alkynyl group may have substituents that are the same as for an alkyl group.
- halo or halogen refer to fluoro, chloro, bromo or iodo, usually regarding halo substitution for a hydrogen atom in an organic compound. Of the halos, chloro and fluoro are generally preferred with chloro generally being the more preferred.
- amino encompasses molecules in which an amine N is directly bonded to the central structure, including NH2, alkylamino and alkenylamino groups.
- acyl refers to hydrogen, alkyl, partially saturated or fully saturated cycloalkyl, partially saturated or fully saturated heterocycle, and aryl substituted carbonyl groups.
- aryl refers to a substituted or unsubstituted aromatic hydrocarbon ring group having 5 to about 30 carbon atoms with from about 6 to about 14 carbon atoms being preferred.
- the "aryl” group can have a single ring or multiple condensed rings. When a substituent is identified as an aryl substituent, an atom of the aryl ring is bonded directly to an atom of the reminder of the structure.
- An aryloxy substituent is an aryl group connected to the remainder of the structure by an -O- bridge.
- the aryl group may have substituents that are the same as for an alkyl group, plus alkyl, alkenyl or alkynyl substituents.
- aryl includes, but is not limited to phenyl, ⁇ -naphthyl, ⁇ -naphthyl, biphenyl, anthryl, tetrahydronaphthyl, fiuorenyl, indanyl, biphenylenyl, and acenaphthenyl. Specifically included within the definition of “aryl” are those aromatic groups that are optionally substituted.
- the, "aryl" groups are optionally substituted with from 1 to 5 substituents selected from the group consisting of acyloxy, hydroxy, acyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, amino, amino substituted by one or two alkyl groups of from 1 to 6 carbon atoms, aminoacyl, acylamino, azido, cyano, halo, nitro, thioalkoxy, trihalomethyl, and aryl.
- substituents selected from the group consisting of acyloxy, hydroxy, acyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, amino, amino substituted by one or two alkyl groups of from 1 to 6 carbon atoms, amino
- aralkyl embraces aryl-substituted alkyl moieties.
- Preferable aralkyl groups are "lower aralkyl” groups having aryl groups attached to alkyl groups having one to six carbon atoms. Examples of such groups include benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl.
- carbocyclic refers to an optionally substituted group that contains one or more covalently closed ring structures, and that the atoms forming the backbone of the ring are all carbon atoms. The term thus distinguishes carbocyclic from heterocyclic rings in which the ring backbone contains at least one non-carbon atom.
- cycloalkane or “cyclic alkane” or “cycloalkyl” refer to a carbocyclic group in which the ring is an optionally substituted cyclic aliphatic hydrocarbon, for example, a cyclic alkyl group preferably with 3 to 12 ring carbons.
- Cycloalkyl includes, by way of example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl, and the like.
- heterocyclic or heterocycle means an optionally substituted, saturated or unsaturated, aromatic or non-aromatic cyclic hydrocarbon group with 4 to about 20 carbon atoms, preferably about 5 to about 6, wherein 1 to about 4 carbon atoms are replaced by nitrogen, oxygen or sulfur.
- the preferred heterocycles are selected from the group consisting of benzimidazole, dihydrothiophene, dioxin, dioxane, dioxolane, dithiane, dithiazine, dithiazole, dithiolane, furan, imidazole, morpholine, oxazole, oxadiazole, oxathiazole, oxathiazolidine, oxazine, oxadiazine, piperazine, piperidine, pyran, pyrazine, pyrazole, pyridine, pyrimidine, pyrrole, pyrrolidine, tetrahydrofuran, tetrazine, thiadiazine, thiadiazole, thiatriazole, thiazine, thiazole, thiomorpholine, thiophene, thiopyran, triazine, and triazole. Structures of some heterocycles are as follows:
- heteroaryl is defined as a substituted or unsubstituted aromatic heterocyclic ring system (monocyclic or bicyclic). Heteroaryl groups can have, for example, from about 4 to about 20 carbon atoms (unless explicitly specified otherwise) with from about 4 to about 10 being preferred. In some embodiments, heteroaryl groups are aromatic heterocyclic rings systems havmg about 4 to about 14 ring atoms and containing carbon atoms and 1, 2, 3, or 4 heteroatoms selected from oxygen, nitrogen or sulfur.
- heteroaryl groups are furan, thiophene, indole, azaindole, oxazole, thiazole, isoxazole, isothiazole, imidazole, N-methylimidazole, pyridine, pyrimidine, pyrazine, pyrrole, N-methylpyrrole, pyrazole, N-methylpyrazole, 1,3,4-oxadiazole, 1,2,4-triazole, 1 -methyl- 1,2,4-triazo Ie, IH- tetrazole, 1-methyltetrazole, benzoxazole, benzothiazole, benzo furan, benzisoxazole, benzimidazole, N-methylbenzimidazole, azabenzimidazole, indazole, quinazoline, quinoline, and isoquinoline.
- bridged ring refers to group of 6 to 12 atoms that form an optionally substituted carbocycle, heterocycle, aryl, or heteroaryl comprising one or more rings wherein two or more non- adjacent ring atoms are connected.
- Nonlimiting examples of a bridged ring structure may include a triccycloalkane, such as, for example, adamantanyl.
- the compounds of the present subject matter can exist in tautomeric, geometric or stereoisomeric forms.
- the present subject matter contemplates all such compounds, including cis- and trans-geometric isomers, E- and Z-geometric isomers, R- and S-enantiomers, diastereomers, d-isomers, 1 -isomers, the racemic mixtures thereof and other mixtures thereof, as falling within the scope of the present subject matter.
- pharmaceutically acceptable carrier refers to any inactive ingredient present in one of the herein described compositions in an amount effective to enhance the stability, effectiveness, or otherwise of said composition.
- pharmaceutically acceptable carriers include diluents, excipients, suspending agents, lubricating agents, adjuvants, vehicles, delivery systems, emulsifiers, disintegrants, absorbants, adsorbents, preservatives, surfactants, colorants, flavorants, emollients, buffers, pH modifiers, thickeners, water softening agents, humectants, fragrances, stabilizers, conditioning agents, chelating agents, sweeteners, propellants, anticaking agents, viscosity increasing agents, solubilizers, plasticizers, penetration enhancing agents, glidants, film forming agents, fillers, coating agents, binders, antioxidants, stiffening agents, wetting agents, or any mixture of these components.
- salts refers to salts of certain ingredient(s) which possess the same activity as the unmodified compound(s) and which are neither biologically nor otherwise undesirable.
- a salt can be formed with, for example, organic or inorganic acids.
- Non-limiting examples of suitable acids include acetic acid, acetylsalicylic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzoic acid, benzenesulfonic acid, bisulfic acid, boric acid, butyric acid, camphoric acid, camphorsulfonic acid, carbonic acid, citric acid, cyclopentanepropionic acid, digluconic acid, dodecylsui ⁇ c acid, ethanesulfonic acid, formic acid, fumaric acid, glyceric acid, glycerophosphoric acid, glycine, glucoheptanoic acid, gluconic acid, glutamic acid, glutaric acid, glycolic acid, hemisulfic acid, heptanoic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, hydroxyethanesulfonic acid, lactic acid,
- subject or “individual” or “animal” or “patient” or “mammal,” refers to any subject, particularly a mammalian subject, for whom diagnosis, prognosis, or therapy is desired, for example, a human.
- a "treatment” or “treating” of a disease, disorder, or condition encompasses alleviation of at least one symptom thereof, a reduction in the severity thereof, or the delay, prevention, or inhibition of the progression thereof. Treatment need not mean that the disease, disorder, or condition is totally cured.
- a useful composition herein needs only to reduce the severity of a disease, disorder, or condition, reduce the severity of symptoms associated therewith, provide improvement to a patient or subject's quality of life, or delay, prevent, or inhibit the onset of a disease, disorder, or condition.
- the term "modulating" means that a compound of the present subject matter may be an activator or inhibitor of Hsp70 or Hsc70.
- An activator would promote the HSP pathways, activators would be useful for diseases where incresed proliferation may have a beneficial therapeutic effect.
- An inhibitor would inhibit Hsp70 or Hsc70 and thereby inhibit the HSP pathway and inhibit the growth of various cancers and proliferative disorders. Consequently, in conditions where increased activity of HSP pathways is required, then an activator is preferred. In conditions where inhibition of the HSP pathway is required, then an inhibitor is preferred.
- the compounds of the present subject matter are useful in the treatment of proliferative disorders.
- proliferative disorder refers to cancer, including breast, prostate, lung, colon, stomach, pancreatic, ovarian, brain and hematopoietic cancers, esophageal carcinoma, renal cell carcinoma, bladder cancer, head and neck cancer, leukemias, and sarcomas such as cholangiosarcoma and esophageal sarcoma.
- this includes breast and ovarian cancers, prostate cancer, pancreatic cancer, hepatocellular carcinoma, non-small- and small-cell lung cancer (NSCLL, mm u ⁇ ⁇ , cancer, leukemia, and lymphoma.
- NSCLL non-small- and small-cell lung cancer
- mm u ⁇ ⁇ cancer
- leukemia leukemia
- lymphoma lymphoma
- metastatic cancers such as, for example, metastatic breast cancer.
- an "oncoprotein” means a protein that can potentially induce or facilitate neoplastic transformation of a cell.
- the protein can be encoded by an oncogene.
- An oncogene as used herein is a gene that produces a gene product that can potentially induce or facilitate neoplastic transformation of a cell.
- An oncogene can have a viral or cellular origin.
- Nonlimiting examples of oncoproteins include growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, methyltransferases and transcription factors. When these proteins are aberrantly expressed, activated or translocated within the cell after structural and/or regulatory changes, uncontrolled cell proliferation and deficit in cell death can result.
- Nonlimiting examples of an oncoprotein of the present subject matter include ErbB2 (Her2/Neu), EGFR/ErbBl, ErbB3, ErbB4, ErbB5 and any other erbB family members, PDGFR, PML-RAR AKT, BCR-abl, src, Raf family members (e.g., C-Raf, B-Raf), dominant negative p53, HIF-l ⁇ , Telomerase, MTG8 (myeloid leukemia protein), Heat Shock factor, Hepatitis B virus reverse transcriptase, c-src, v-src, mutated or absent p53, estrogen receptor, mutant K-ras proteins, nitric oxide synthase and chimeric protein p210 BCR - ABL individually and/or in any combination.
- ErbB2 Her2/Neu
- EGFR/ErbBl ErbB3, ErbB4, ErbB5 and any other erbB family members
- PDGFR P
- the present invention further includes any other oncoprotein now known or later identified to be associated with Hsp70 or the Hsp70-Hsp90 complex.
- the oncoproteins present in a patient are measured before, during, and after therapy.
- administering compounds of the present subject matter to a patient in need thereof results in the destabilization and degradation of one or more oncoproteins in the patient.
- any concentration ranges, percentage range, or ratio range recited herein are to be understood to include concentrations, percentages or ratios of any integer within that range and fractions thereof, such as one tenth and one hundredth of an integer, unless otherwise indicated.
- Xi, X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , and Xg are independently selected from CH, substituted C, and substituted N;
- Xio and Xn are independently selected from CH, CH 2 , NH, NR, O, and S such that aromaticity is maintained;
- R is an alkyl or substituted alkyl chain;
- Y is S, SO, SO 2 , CH 2 , CHR, CRR, CO, O, NH, or NR, wherein R is a lower alkyl or alkoxyl chain;
- Z is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, - NHSO2alkenyl, -NHCOalkenyl,
- Wi and W 2 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, -NHCOalkenyl, - NHCOalkynyl, -COalkenyl, -COalkynyl, trihalocarbon, thioalkyl, SO 2
- W 3 and W 4 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, -NHCOalkenyl, - NHCOalkynyl, -COalkenyl, -COalkynyl, trihalocarbon, thioalkyl, SO
- W 2 may be joined to the right side aryl ring directly to form a 5-membered ring or via a linker to form a 6 or 7-membered ring.
- X 1 -X 4 are independently selected from but not limited to:
- X 5 -X 9 are independently selected from but not limited to:
- X 1O is CH 2 , NH, NR', O, and S; wherein R' is a lower alkyl chain;
- Y is S, SO, SO 2 , O or CH2.
- Z is alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted substituted and unsubstituted amido, alkylamido, and dialkylamido.
- Wj and W 2 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted substituted and unsubstituted amido, alkylamido, and dialkylamido; Wi and W 2 may be joined together via a linker, so as to form a fused 5- or 6-membered ring.
- W 3 and W 4 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido; W 3 and W 4 may be joined together via a linker, so as to form a fused 5- or 6-membered ring.
- the compound of formula (I) or (F) is as defined above, provided that: (1) Y is selected from the group consisting of S, SO, and SO2; (2) Z is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, alkoxy, alkylamino, dialkyl amino, cycloalkylamino, arylamino, and diarylamino; (3) the left-side aryl of formula Ia or Ia' contains at least one ring nitrogen; (4) at least one of Wl and W2 is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, and diarylamino; and (5) at least one of W3 and W4 is
- the compound of formula (I) or (F) is as defined above, provided that: (1) Z is selected from the group consisting of aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, alkylamino, dialkyl amino, cycloalkylamino, arylamino, and diarylamino; (2) at least one of Wl and W2 is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, alkylamino, dialkylamino, cycloalkylamino., arylamino, and diarylamino; and (3) at least one of W3 and (4) W4 is selected from the group consisting of amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted or unsubstituted amido, -NH
- the compound of formula (I) or (F) is as defined above, provided that: (1) Y is selected from the group consisting of S, SO, and SO2; (2) Z is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, alkoxy, alkylamino, dialkyl amino, cycloalkylamino, arylamino, and diarylamino; (3) at least one of Wl and W2 is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, and diarylamino; and (4) at least one of W3 and W4 is selected from the group consisting of amino, alkylamino, dialkylamino, cycl
- the compound of formula (I) or (F) is as defined above, provided that: (1) Z is selected from the group consisting of aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, alkoxy, alkylamino, dialkyl amino, cycloalkylamino, arylamino, and diarylamino; (2) both Wl and W2 are selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, and diarylamino; and (3) at least one of W3 and W4 is selected from the group consisting of amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted or unsubstituted amido
- the compound of formula (I) or (F) is as defined above, provided that: (1) both Wl and W2 are selected from the group consisting of aryl, heterocycle, alkoxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, and diarylamino; and (4) at least one of W3 and W4 is selected from the group consisting of amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted or unsubstituted amido, -NHSO 2 alkenyl, -NHCOalkenyl, -NHCOalkynyl, -COalkenyl, - COalkynyl, alkylamido, alkylsulfonamido, and sulfonamido.
- the compound of formula (I) or (F) is as defined above, provided that: (1) Y is selected from the group consisting of S, SO, and SO2; (2) Z is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, alkoxy, alkylamino, dialkyl amino, cycloalkylamino, arylamino, and diarylamino; (3) either the left-side aryl or the right-side aryl of formula Ia or Ia' contains at least two ring nitrogens; (4) at least one of Wl and W2 is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, and diarylamino; and (5)
- the compound of formula (I) or (F) is as defined above, provided that: (1) Y is selected from the group consisting of S, SO, and SO2; (2) Z is selected from the group consisting of aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, alkoxy, alkylamino, dialkyl amino, cycloalkylamino, arylamino, and diarylamino; (3) either the left-side aryl or the right-side aryl or both aryls of formula Ia or Ia' contain at least two ring nitrogens; (4) at least one of Wl and W2 is selected from the group consisting of alkoxy, alkylamino, dialkylamino, cycloalkylamino, arylamino, and diarylamino; and (5) at least one of W3 and W4 is selected from the group consisting of alkylamino, dialkylamino, cycloalkylamin
- X 5 -X 9 are independently selected from CH, substituted C, and substituted N;
- Y is S, SO, SO 2 , CH 2 , CHR, CRR, CO, O, NH, or NR, wherein R is a lower alkyl or alkoxyl chain;
- Z is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, - NHCOalkenyl, -NHCOalkynyl, -COalkenyl, -COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, - COO-alkyl, -CO
- Wi and W 2 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, -NHCOalkenyl, -NHCOalkynyl, -COalkenyl, - COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, -COO
- W 3 and W 4 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylammo, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, -NHCOalkenyl, -NHCOalkynyl, -COalkenyl, - COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, -C
- W 2 may be joined to the right side aryl ring directly to form a 5-membered ring or via a linker to form a 6 or 7-membered ring.
- X 5 -Xg are independently selected from but not limited to:
- Y is S, SO, SO 2 , O or CH 2 .
- Z is alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- Wi and W 2 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- W 3 and W 4 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- Y is S, SO, or SO 2 .
- Z is hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, alkoxy, alkylamino, dialkyl amino, cycloalkylamino, arylamino, or diarylamino.
- W] and W 2 are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylammo, or diarylamino.
- W 3 and W 4 are independently hydrogen, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylammo, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, -NHCOalkenyl, -NHCOalkynyl, -COalkenyl, -
- Table 1 shows examples of specific compounds exemplifying this embodiment.
- IC50 values listed for some of these compounds illustrate the antiproliferative effects of the subject compounds and were obtained using the Growth Inhibition assays described herein.
- One embodiment of the compound of formula 2a is a compound of formula 2a'
- the compound of formula 2a' is as described above, provided that X does not comprise a bridged ring structure.
- the compound of formula 2a' is as described above, provided that at least one of the X or Y substituents comprises at least one label or marker group useful for identifying, tracking, and or isolating the compound.
- label groups and marker groups useful herein include, for example, fluorescent groups, biotin groups, avidin groups, and enzyme linker groups.
- Another embodiment of the present subj ect matter is a compound of formula 2a' '
- each R 1 is independently selected from the group consisting of H; optionally substituted straight or branched alkyl, alkenyl, or alkynyl; an optionally substituted carbocyclic, heterocyclic, aryl, or heteroaryl group; halo; an optionally substituted C 2-22 acyl group; a -C(O)R 6 group; and an - (ethoxy) n -R ⁇ group, wherein n is 1-12; R 2 , R 3 , R 4 , and R 5 are each independently selected from the group consisting of H; optionally substituted straight or branched alkyl, alkenyl, or alkynyl; an optionally substituted carbocyclic, heterocyclic, aryl, or heteroaryl group; an optionally substituted C 2-22 acyl group; a -C(O)R 6 group; and an optionally substituted alkoxycarbonyl group
- each R 6 is independently selected from the group consisting of an optionally substituted straight or branched alkyl, alkenyl, or alkynyl; an optionally substituted carbocyclic, heterocyclic, aryl, or heteroaryl group; an optionally substituted alkyloxy group; and an alkylacrylate group (such as ethyl acrylate); provided that X does not comprise a bridged ring structure.
- the compound of formula 2a' is as described above, provided that the compound is not N-(6-amino-2-(4,6-dimethoxy-2-(4-methylpiperazin-l- yl)pyrimidin-5-ylthio) pyrimidin-4-yl)octanamide (YK20).
- each R 1 is independently selected from the group consisting of H; and optionally substituted straight or branched alkyl, alkenyl, or alkynyl
- R 2 , R 3 , R 4 , and R 5 are each independently selected from the group consisting of H; optionally substituted straight or branched C1-C6 alkyl; and -C(O) R 6 wherein R 6 is an optionally substituted straight or branched C1-C6 alkyl, alkenyl, or alkynyl
- X is selected from the group consisting of an optionally substituted straight or branched alkyl, alkenyl, or alkynyl group; an optionally substituted carbocyclic, heterocyclic, aryl, or heteroaryl group; and halo, hi a further embodiment, X is piperazine ring linked at a nitrogen atom, wherein the piperazine is optionally substituted
- each R 1 is independently selected from the group consisting of straight or branched Cl- C6 alkyl and substituted straight or branched C1-C6 alkyl.
- Ri may be selected from the group consisting of methyl, ethyl, ethenyl, propyl, and butyl.
- each Ri is independently selected from methyl and ethyl
- NR 2 R 3 is NH 2
- NR 4 Rs is NHC(O)-Cl-Co alkyl or NHC(O)-C2-C6 alkenyl
- X is piperazine ring linked at a nitrogen atom, and the piperazine ring is optionally substituted with halo, haloalkyl, or straight or branched C1-C6 alkyl.
- each Ri is the same or different and is methyl or ethyl
- R 2 , R 3 , and R 4 are each H
- R 5 is -C(O)-methyl, -C(O)-ethyl, or -C(O)-ethenyl
- X is piperazine, 4-methylpiperazin-l-yl or 4-(2-(2- (2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)piperazin- 1 -yl.
- X 5 -X 9 are independently selected from CH, substituted C, and substituted N;
- Y is S, SO, SO 2 , CH 2 , CHR, CRR, CO, O, NH, or NR, wherein R is a lower alkyl or alkoxyl chain;
- Z is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino,
- Wi and W 2 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, -NHCOalkenyl, -NHCOalkynyl, -COalkenyl, - COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, -COO
- W 3 and W 4 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, -NHCOalkenyl, -NHCOalkynyl, -COalkenyl, - COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, -C
- X 5 -Xg are independently selected from but not limited to:
- Y is S, SO, SO 2 , O or CH 2 .
- Z is alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- W 1 and W 2 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- cycloalkylamino arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- W 3 and W 4 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- cycloalkylamino arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- Y is S, SO, or SO 2 .
- Z is U ⁇ u 5 Ui, mj., alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, alkoxy, alkylamino, dialkyl amino, cycloalkylamino, arylamino, or diarylamino.
- W 1 and W 2 are
- alkyl independently hydrogen, alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, or diarylamino.
- W 3 and W 4 are
- Table 2 show examples of specific compounds exemplifying this embodiment.
- X 5 -X 9 are independently selected from CH, substituted C, and substituted N;
- Y is S, SO, SO 2 , CH 2 , CHR, CRR, CO, O, NH, or NR, wherein R is a lower alkyl or alkoxyl chain;
- Z is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino,
- dialkylamino cyclo alkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, - NHCOalkenyl, -NHCOalkynyl, -COalkenyl, -COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, - COO-alkyl, -COalkyl, and alkyl-CN;
- Wi and W 2 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, -NHCOalkenyl, -NHCOalkynyl, -COalkenyl, - COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, -COO
- W 3 and W 4 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, -NHCOalkenyl, -NHCOalkynyl, -COalkenyl, - COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, -C
- X 5 -Xg are independently selected from but not limited to:
- Y is S, SO, SO 2 , O or CH 2 .
- Z is alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- Wi and W 2 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- cycloalkylamino arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- W 3 and W 4 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- cycloalkylamino arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- Y is S, SO, or SO 2 .
- Z is hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, alkoxy, alkylamino, dialkyl amino, cycloalkylamino, arylamino, or diarylamino.
- Wi and W 2 are
- alkyl independently hydrogen, alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, or diarylamino.
- W 3 and W 4 are
- alkyl-CN independently hydrogen, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, -NHCOalkenyl, -NHCOalkynyl, -COalkenyl, - COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, -COO-alkyl, -COalkyl, and alkyl-CN.
- Table 3 show examples of specific compounds exemplifying this embodiment.
- X 5 -X 9 are independently selected from CH, substituted C, and substituted N;
- Y is S, SO, SO 2 , CH 2 , CHR, CRR, CO, O, NH, or NR, wherein R is a lower alkyl or alkoxyl chain;
- Z is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino,
- W 1 and W 2 independently at each occurrence are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- W 3 and W 4 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, -NHCOalkenyl, -NHCOalkynyl, -COalkenyl, - COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, -C
- X 5 -Xg are independently selected from but not limited to:
- Y is S, SO, SO 2 , O or CH2.
- Z is alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- Wi and W 2 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- cycloalkylamino arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- W 3 and W 4 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- cycloalkylamino arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- Y is S, SO, or SO 2 .
- Z is ny ⁇ rogen, ai ⁇ yi, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, alkoxy, alkylamino, dialkyl amino, cycloalkylamino, arylamino, or diarylamino.
- Wi and W 2 are
- alkyl independently hydrogen, alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, or diarylamino.
- W 3 and W 4 are identical to each other.
- alkyl-CN independently hydrogen, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, -NHCOalkenyl, -NHCOalkynyl, -COalkenyl, - COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, -COO-alkyl, -COalkyl, and alkyl-CN.
- Table 4 show examples of specific compounds exemplifying this embodiment.
- X 5 -Xg are independently selected from CH, substituted C, and substituted N;
- Y is S, SO, SO 2 , CH 2 , CHR, CRR, CO, O, NH, or NR, wherein R is a lower alkyl or alkoxyl chain;
- Z is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino,
- W 1 and W 2 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido,
- alkylsulfonamido, sufonamido, -NHSO2alkenyl, -NHCOalkenyl, -NHCOalkynyl, -COalkenyl, - COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, -COO-alkyl, -COalkyl, ana ai ⁇ yi-L.iN; or W 1 ana W 2 may be joined together via a linker, so as to form a fused 5- or 6-membered ring; and
- W 3 and W 4 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido,
- W 2 may be joined to the right side aryl ring directly to form a 5-membered ring or via a linker to form a 6 or 7-membered ring.
- X 5 -X 9 are independently selected from but not limited to:
- Y is S, SO, SO 2 , O or CH2.
- Z is alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- Wi and W 2 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- cycloalkylamino arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- W 3 and W 4 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- Y is S, SO, or SO 2 .
- Z is hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, alkoxy, alkylamino, dialkyl amino, cycloalkylamino, arylamino, or diarylamino.
- Wi and W 2 are
- alkyl independently hydrogen, alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, or diarylamino.
- W 3 and W 4 are
- Table 5 show examples of specific compounds exemplifying this embodiment.
- X 5 -Xg are independently selected from CH, substituted C, and substituted N;
- Y is S, SO, SO 2 , CH 2 , CHR, CRR, CO, O, NH, or NR, wherein R is a lower alkyl or alkoxyl chain;
- Z is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, - NHCOalkenyl, -NHCOalkynyl, -COalkenyl, -COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, - COO-alkyl, -CO
- W 1 and W 2 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido,
- W 3 and W 4 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido,
- W 2 may be joined to the right side aryl ring directly to form a 5-membered ring or via a linker to form a 6 or 7-membered ring.
- X 5 -X 9 are independently selected from but not limited to:
- Y is S, SO, SO 2 , O or CH2.
- Z is alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- Wi and W 2 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- cycloalkylamino arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- W 3 and W 4 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- cycloalkylamino arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- Y is S, SO, or SO 2 .
- Z is hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, alkoxy, alkylamino, dialkyl amino, cycloalkylamino, arylamino, or diarylamino.
- W 1 and W 2 are identical to each other.
- alkyl independently hydrogen, alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, or diarylamino.
- W 3 and W 4 are
- alkyl-CN independently hydrogen, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, -NHCOalkenyl, -NHCOalkynyl, -COalkenyl, - COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, -COO-alkyl, -COalkyl, and alkyl-CN.
- Table 6 show examples of specific compounds exemplifying this embodiment. Table 6
- X 10 and Xn are independently selected from CH, CH 2 , NH, NR', O, and S such that aromaticity is maintained, wherein R' is an alkyl or substituted alkyl chain;
- Y is S, SO, SO 2 , CH 2 , CHR, CRR, CO, O, NH, or NR, wherein R is a lower alkyl or alkoxyl chain;
- Z is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino,
- W 1 and W 2 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido,
- W 3 and W 4 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido,
- W 2 may be joined to the right side aryl ring directly to form a 5-membered ring or via a linker to form a 6 or 7-membered ring.
- Xi 0 and Xi i are independently selected from but not limited to:
- R is an alkyl or substituted alkyl chain.
- Y is S, SO, SO 2 , O or CH2.
- Z is alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- W 1 and W 2 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- cycloalkylamino arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- W 3 and W 4 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- cycloalkylamino arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- R is an alkyl or substituted alkyl chain.
- Y is S, SO, or SO 2 .
- Z is hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, alkoxy, alkylamino, dialkyl amino, cycloalkylamino, arylamino, or diarylamino.
- alkyl independently hydrogen, alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, or diarylamino.
- alkyl-CN independently hydrogen, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, -NHCOalkenyl, -NHC ⁇ aiKynyi, -u ⁇ ai ⁇ enyi, COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, -COO-alkyl, -COalkyl, and alkyl-CN.
- Table 7 show examples of specific compounds exemplifying this embodiment.
- Xio and Xn are independently selected from CH, CH 2 , NH, NR', O, and S such that aromaticity is maintained, wherein R' is an alkyl or substituted alkyl chain;
- Y is S, SO, SO 2 , CH 2 , CHR, CRR, CO, O, NH, or NR, wherein R is a lower alkyl or alkoxyl chain;
- Z is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, - NHCOalkenyl, -NHCOalkynyl, -COalkenyl, -COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, - COO-alkyl, -CO
- Wi and W 2 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido,
- W 3 and W 4 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido,
- W 2 may be joined to the right side aryl ring directly to form a 5-membered ring or via a linker to form a 6 or 7-membered ring.
- Xi 0 and Xi i are independently selected from but not limited to: wherein R is an alkyl or substituted alkyl chain.
- Y is S, SO, SO 2 , O or CH2.
- Z is alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- Wi and W 2 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- cycloalkylamino arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- W 3 and W 4 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- cycloalkylamino arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- R is an alkyl or substituted alkyl chain.
- Y is S, SO, or SO 2 .
- Z is hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, alkoxy, alkylamino, dialkyl amino, cycloalkylamino, arylamino, or diarylamino.
- Wi and W 2 are
- alkyl independently hydrogen, alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, or diarylamino.
- W 3 and W 4 are
- alkyl-CN independently hydrogen, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, -NHCOalkenyl, -NHCOalkynyl, -COalkenyl, - COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, -COO-alkyl, -COalkyl, and alkyl-CN.
- Table 8 show examples of specific compounds exemplifying this embodiment.
- Xio and Xn are independently selected from CH, CH 2 , NH, NR', O, and S such that aromaticity is maintained, wherein R' is an alkyl or substituted alkyl chain;
- Y is S, SO, SO 2 , CH 2 , CHR, CRR, CO, O, NH, or NR, wherein R is a lower alkyl or alkoxyl chain;
- Z is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, - NHCOalkenyl, -NHCOalkynyl, -COalkenyl, -COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, - COO-alkyl, -CO
- Wi and W 2 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido,
- W 3 and W 4 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, aikylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, -NHCOalkenyl, -NHCOalkynyl, -COalkenyl, - COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl,
- W 2 may be joined to the right side aryl ring directly to form a 5-membered ring or via a linker to form a 6 or 7-membered ring.
- Xio and Xi i are independently selected from but not limited to:
- R is an alkyl or substituted alkyl chain.
- Y is S, SO, SO 2 , O or CH2.
- Z is alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- W 1 and W 2 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- cycloalkylamino arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- W 3 and W 4 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- cycloalkylamino arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- R is an alkyl or substituted alkyl chain.
- Y is S, SO, or SO 2 .
- Z is hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, alkoxy, alkylamino, dialkyl amino, cycloalkylamino, arylamino, or diarylamino.
- W 1 and W 2 are identical to each other.
- alkyl independently hydrogen, alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, or diarylamino.
- W 3 and W 4 are
- Table 9 show examples of specific compounds exemplifying this embodiment.
- X 10 and Xj 1 are independently selected from CH, CH 2 , NH, NR', O, and S such that aromaticity is maintained, wherein R' is an alkyl or substituted alkyl chain;
- Y is S, SO, SO 2 , CH 2 , CHR, CRR, CO, O, NH, or NR, wherein R is a lower alkyl or alkoxyl chain;
- Z is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, - NHCOalkenyl, -NHCOalkynyl, -COalkenyl, -COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, - COO-alkyl, -CO
- Wi and W 2 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido,
- W 1 ana W 2 may be joined together via a linker, so as to form a fused 5- or 6-membered ring;
- W 3 and W 4 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido,
- W 2 may be joined to the right side aryl ring directly to form a 5-membered ring or via a linker to form a 6 or 7-membered ring.
- Xi 0 and X] i are independently selected from but not limited to:
- R is an alkyl or substituted alkyl chain.
- Y is S, SO, SO 2 , O or CH2.
- Z is alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- Wi and W 2 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- W 3 and W 4 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- cycloalkylamino arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- R is an alkyl or substituted alkyl chain.
- Y is S, SO, or SO 2 .
- Z is hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, alkoxy, alkylamino, dialkyl amino, cycloalkylamino, arylamino, or diarylamino.
- Wi and W 2 are
- alkyl independently hydrogen, alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, or diarylamino.
- W 3 and W 4 are
- Table 10 show examples of specific compounds exemplifying this embodiment.
- X 10 and X 11 are independently selected from CH, CH 2 , NH, NR', O, and S such that aromaticity is maintained, wherein R' is an alkyl or substituted alkyl chain;
- Y is S, SO, SO 2 , CH 2 , CHR, CRR, CO, O, NH, or NR, wherein R is a lower alkyl or alkoxyl chain;
- Z is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, - NHCOalkenyl, -NHCOalkynyl, -COalkenyl, -COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, - COO-alkyl, -CO
- W 3 and W 4 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido,
- W 2 may be joined to the right side aryl ring directly to form a 5-membered ring or via a linker to form a 6 or 7-membered ring.
- Xi 0 and Xi i are independently selected from but not limited to:
- R is an alkyl or substituted alkyl chain.
- Y is S, SO, SO 2 , O or CH2.
- Z is alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- Wi and W 2 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- cycloalkylamino arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- W 3 and W 4 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- cycloalkylamino arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- R is an alkyl or substituted alkyl chain.
- Y is S, SO, or SO 2 .
- Z is hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, alkoxy, alkylamino, dialkyl amino, cycloalkylamino, arylamino, or diarylamino.
- Wi and W 2 are
- alkyl independently hydrogen, alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, or diarylamino.
- Table 11 show examples of specific compounds exemplifying this embodiment.
- Xio and Xn are independently selected from CH, CH 2 , NH, NR', O, and S such that aromaticity is maintained, wherein R' is an alkyl or substituted alkyl chain;
- Y is S, SO, SO 2 , CH 2 , CHR, CRR, CO, O, NH, or NR, wherein R is a lower alkyl or alkoxyl chain;
- Z is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSuzai ⁇ enyi, - NHCOalkenyl, -NHCOalkynyl, -COalkenyl, -COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, - COO-alkyl, -
- W 1 and W 2 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido,
- W 3 and W 4 independently at each occurrence can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido,
- W 2 may be joined to the right side aryl ring directly to form a 5-membered ring or via a linker to form a 6 or 7-membered ring.
- Xj 0 and Xj ⁇ are independently selected from but not limited to:
- R is an alkyl or substituted alkyl chain.
- Y is S, SO, SO 2 , O or CH2.
- Z is alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- Wi and W 2 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- cycloalkylamino arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- W 3 and W 4 at each occurrence are independently selected from the group consisting of hydrogen, alkyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino,
- cycloalkylamino arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, and dialkylamido.
- R is an alkyl or substituted alkyl chain.
- Y is S, SO, or SO 2 .
- Z is hydrogen, alkyl, alkenyl, alkynyl, aryl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocycle, halogen, hydroxyl, alkoxy, alkylamino, dialkyl amino, cycloalkylamino, arylamino, or diarylamino.
- alkyl independently hydrogen, alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, or diarylamino.
- alkyl-CN independently hydrogen, halogen, hydroxyl, nitro, cyano, aryloxy, alkoxy, halogenated alkoxy, alkenyloxy, hydroxyalkyl, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, acylamino, carbamyl, substituted and unsubstituted amido, alkylamido, alkylsulfonamido, sufonamido, -NHSO2alkenyl, -NHCOalkenyl, -NHCwai ⁇ ynyi, - ⁇ uaiKenyi, ⁇ COalkynyl, trihalocarbon, thioalkyl, SO 2 -alkyl, -COO-alkyl, -COalkyl, and alkyl-CN.
- Table 12 show examples of specific compounds exemplifying this embodiment.
- the compound of the present subject matter is a compound selected from the group consisting of compounds of Table 1, compounds of Table 2, compounds of Table 3, compounds of Table 4, compounds of Table 5, compounds of Table 6, compounds of Table 7, compounds of Table 8, compounds of Table 9, compounds of Table 10, compounds of Table 11, and compounds of Table 12.
- the present subject matter relates to a method of making a compound, or an intermediate thereof, comprising performing at least one of the synthetic steps described in the examples herein.
- a cavity in the Hsp70 protein that has no known naturally occurring or synthetically created ligand, when occupied by compounds of the present subject matter as described herein, results in inhibition of malignant cell growth, inhibition of aberrant cell cycle progression, degradation and inhibition of one or more oncoproteins, induction of apoptosis, reduction in the invasive potential of cancer cells at doses that are not toxic to normal cells, or combinations thereof.
- occupancy of this previosuly unexplored pocket by other small molecule ligands will lead to all or a subset of the following effects, but is not limited to: inhibition of malignant cell growth, inhibition of aberrant cell cycle progression, degradation and inhibition of several onco-protems, induction of apoptosis, reduction in the invasive potential of cancer cells at doses that are not toxic to normal cells, or combinations thereof.
- the pocket referred to herein as an allosteric Site 1
- the pocket is next to the ATP/ADP binding pocket, and is comprised of a hydrophilic sub-pocket lined by but not limited to Thrl3, Thrl4, Tyrl5, Lys56, Lys271, Arg269, Glu268, Arg264 and Thr265 polar amino acids.
- Cysteine residue Cys267 embedded in this sub-pocket that could covalently link to a ligand containing the appropriate Cys-reactive functionality, such as but not limited to acrylamide, vinyl sulfonamide, propiolamide or ⁇ -halocarbonyl.
- Providing interactions with the ligand are amino acids such as but not limited to Lys88, His89, Trp90, Pro91 and Phe92.
- a method of treating or preventing a tumor or proliferative disorder in an animal comprising administering a therapeutically effective amount of an Hsp70 inhibitor to an animal in need thereof; contacting the Hsp70 inhibitor with an allosteric binding domain located outside the nucleotide binding site of Hsp70 and Hsc70; simultaneously inhibiting both Hsp70 and Hsc70; inducing apoptosis in tumor cells or cells with a proliferative disorder; and not inducing increased apoptosis in normal cells, stroma, or blood vessels, hi a further embodiment, the Hsp70 inhibitor used in the above method is a compound selected from formula (I) or (F).
- the allosteric binding domain is located on SEQ ID NO: 1
- said domain is defined by one or more amino acid residues selected from the group consisting of Thrl3, Thrl4, Tyrl5, Lys56, Lys271, Arg269, Glu268, Arg264, Thr265, Cys267, Leu237, Val238, Val260, Arg261, Val59, Pro63, Thr66, Asn235, Asp234, Glu231, Asp69, Phe68, Tyr41, Lys88, His89, Trp90, Pro91, Phe92, and combinations thereof.
- the allosteric binding domain is 1 defined by three or more amino acid residues recited above, hi another embodiment, the allosteric binding domain is 1 defined by four or more amino acid residues recited above.
- the allosteric binding domain is 1 defined by five or more amino acid residues recited above. In another embodiment, the allosteric binding domain is 1 defined by 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more amino acid residues recited above. In some embodiments, a compound of the present subject matter binds to this allosteric binding domain and causes the inhibition of Hsp70, Hsc70, or both simultaneously.
- the allosteric binding domain is located on SEQ ID NO: 1
- the domain is defined by one or more amino acid residues selected from the group consisting of Cys267, Leu237, Arg264, Asp234, Arg261, Tyr41, Phe68, Trp90, His89, and combinations thereof.
- the allosteric binding domain is located on SEQ ID NO:1 and said domain is defined by one or more amino acid residues selected from the group consisting of Cys267, Arg264, Arg261, Phe68, His89, and combinations thereof.
- Hsp70 comprises a binding pocket on SEQ ID NO:1 having a Site 1 located in a cleft region outside the ATP/ADP binding domain, and flanked by subregions Ib and lib, and which comprises contacting Site 1 of the binding pocket with a ligand which binds to the binding pocket so as to activate the activity of Hsp70.
- a further embodiments involves a method of activating Hsp70 according to claim 27, wherein Site 1 has a first large hydrophilic pocket comprising Tyrl5, Lys56, Lys271, Arg269, Glu268, Arg264 and Thr265 polar amino acids; a Cysteine residue (Cys267) embedded in this pocket; and adjacent to this pocket there is a second larger pocket on Hsp70 comprising both non-polar and polar amino acid residues, such as Leu237, Val238, Val260, Arg261, Val59, Pro63, Thr66, Asn235, Asp234, Glu231, Asp69, Phe68 and Tyr41, which may form hydrophobic and electrostatic ( ⁇ - ⁇ ) interactions.
- binding site [00247] In a further embodiment, a three-dimensional structure is provided of binding site
- Hsp70 or a variant thereof for screening a modulator that modulates the activity of Hsp-70 or Hsc-70
- said binding site comprises a ligand binding domain on SEQ ID NO:1 defined by amino acid residue selected from a group consisting of Thrl3, Thrl4, Tyrl5, Lys56, Lys271, Arg269, Glu268, Arg264, Thr265, Cys267, Leu237, Val238, Val260, Arg261, Val59, Pro63, Thr66, Asn235, Asp234, Glu231, Asp69, Phe68, Tyr41, Lys88, His89, Trp90, Pro91, Phe92, and combinations thereof.
- One embodiemnt relates to computer assisted system for producing a three- dimensional structure of binding site 1 of Hsp70 or a variant thereof of claim 1, wherein the system comprises: (a) a computer readable data storage medium comprising a data storage material encoded with computer readable data, wherein said data comprises at least a portion of peptide sequence SEQ ID NO: 1 and the sequences shown in boxes in Figure 21 (b) a working memory having stored instructions for processing said computer readable data; (c) a central processing unit coupled to said computer readable data storage medium and said working memory for processing said computer readable data into said three-dimensional structure; and (d) a display coupled to said central processing unit for displaying said three-dimensional structure.
- the binding site 1 of Hsp70 or a variant thereof on SEQ ID NO:1 is defined by amino acid residue selected from a group consisting of Thrl3, Thrl4, Tyrl5, Lys56, Lys271, Arg269, Glu268, Arg264, Thr265, Cys267, Leu237, Val238, Val260, Arg261, Val59, Pro63, Thr66, Asn235, Asp234, Glu231, Asp69, Phe68, Tyr41, Lys88, His89, T ⁇ 90, Pro91, Phe92, and combinations thereof.
- the present subject matter relates to compositions comprising a compound as described herein.
- the present subject matter relates to pharmaceutical compositions comprising a compound as described herein, and a pharmaceutically acceptable carrier.
- the carriers useful herein may further include one or more compatible solid or liquid filler, diluents, or encapsulating materials which are suitable for human or animal administration.
- Biocompatible carriers are components that do not cause any interactions which substantially reduce the efficacy of the pharmaceutical composition in an ordinary user environment. Possible pharmaceutical carriers must be of sufficiently low toxicity to make them suitable for administration to the subject being treated.
- any non-toxic, inert, and effective carrier may be used to formulate the compositions contemplated herein.
- Suitable pharmaceutically acceptable carriers, excipients, and diluents in this regard are well known to those of skill in the art, such as those described in The Merck Index, Thirteenth Edition, Budavari et al., Eds., Merck & Co., Inc., Rahway, NJ. (2001); and the "Inactive Ingredient Guide", U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Office of Management, the contents of all of which are hereby incorporated by reference in their entirety.
- Examples of preferred pharmaceutically acceptable excipients, carriers and diluents useful in the present compositions include distilled water, physiological saline, Ringer's solution, dextrose solution, Hank's solution, and DMSO.
- the carrier may comprise, in total, from about 0.1% to about 99.99999% by weight of the compositions presented herein.
- the compounds of formula (I) and formula (F) have been found to possess anti-pro liferative activity and are therefore believed to be of use in the treatment of proliferative disorders such as cancers and other disorders associated with uncontrolled cellular proliferation.
- an anti-proliferative effect within the scope of the present subject matter may be demonstrated, for example, by the ability to inhibit cell proliferation specific kinases in vitro or in vivo, or inhibit cell proliferation in an in vitro whole cell assay, in an in vivo animal model, or in human clinical administration.
- compositions of the present subject matter may be adapted for oral, rectal, vaginal, parenteral, intramuscular, intraperitoneal, intraarterial, intrathecal, intrabronchial, subcutaneous, intradermal, intravenous, nasal, buccal, or sublingual routes of administration.
- compositions for oral administration, particular use is made of compressed tablets, piUs, tablets, gellules, drops, and capsules.
- these compositions contain from 1 to 250 mg and more preferably from 10-100 mg, of active ingredient per dose.
- compositions or emulsions which may be injected intravenously, intraarterially, intrathecally, subcutaneously, intradermally, intraperitoneally or intramuscularly, and which are prepared from sterile or sterilisable solutions.
- compositions of the present subject matter may also be in form of suppositories, pessaries, suspensions, emulsions, lotions, ointments, creams, gels, sprays, solutions or dusting powders.
- an alternative means of transdermal administration is by use of a skin patch.
- the active ingredient can be incorporated into a cream consisting of an aqueous emulsion of polyethylene glycols or liquid paraffin.
- the active ingredient can also be incorporated, at a concentration of between 1 and 10% by weight, into an ointment consisting of a white wax or white soft paraffin base together with such stabilisers and preservatives as may be required.
- Injectable forms may contain between 10-1000 mg, preferably between 10-250 mg, of active ingredient per dose.
- compositions may be formulated in unit dosage form, i.e., in the form of discrete portions containing a unit dose, or a multiple or sub-unit of a unit dose.
- Appropriate dosage levels on the order of about 0.001 mg to about 5,000 mg per kilogram body weight of the compound active agent may be useful in the treatment of the diseases, disorders, and conditions contemplated herein.
- this effective amount of the active agent will generally comprise from about 0.001 mg to about 100 mg per kilogram of patient body weight per day.
- this dosage of active agent can be administered in a single or multiple dosage units to provide the desired therapeutic effect.
- the preferred therapeutically effective dosage will be the amount of a compound of the present subject matter required to obtain a serum, but more preferably tumor, concentration equivalent to the concentration to achieve phenotypic effects in any of the many assays described herein, such as but not limited to growth inhibition of AML Kasumi-1 cells, induction of apoptosis as indicated by caspase 3,7 activation in MOLM- 13 AML cells, degradation of HER-2 and Raf-1 kinases in SKBr3 breast cancer cells, inactivation of p- STAT3 in MDA-MB-468 breast cancer cells selected from the group consisting of 1 nM to 200 uM; 1 nM to 100 uM; 1 nM to 50 uM; 100 nM to 100 uM; 100 nM to 50 uM; 100 nM to 20 uM; 1 nM to 1 uM; and 1 nM to 100 nM.
- the phenotypic effect is the IC50 value for the assay.
- the preferred therapeutically effective dosage will be the amount required to obtain a serum, but more preferably tumor, concentration equivalent to the concentration equivalent to the concentration to achieve phenotypic effects in any of the many assays described herein, such as but not limited to growth inhibition of AML Kasumi-1 cells, induction of apoptosis as indicated by caspase 3,7 activation in MOLM-13 AML cells, degradation of HER-2 and Raf-1 kinases in SKBr3 breast cancer cells, inactivation of p-STAT3 in MDA-MB-468 breast cancer cells selected from the group consisting ofless than 200 uM; less than 100 uM; less than 50 uM; less than 25 uM; less than 15 uM; less than 10 uM; less than 5 uM; less than 2 uM; less than 1 uM; less than 500 nM; less than 200 nM; or less than 100
- compositions can be combined with other therapeutic agents in conjunction with those provided in the above-described compositions.
- amount of pharmaceutically active ingredients that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated, the nature of the disease, disorder, or condition, and the nature of the active ingredients.
- the preferred pharmaceutical compositions may be given in a single or multiple doses daily.
- the pharmaceutical compositions are given from one to three times daily. Starting with a low dose twice daily and slowly working up to higher doses if needed is a strategy.
- the amount of pharmaceutically active ingredients that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated, the nature of the disease, disorder, or condition, and the nature of the active ingredients.
- a specific dose level for any particular patient will vary depending upon a variety of factors, including the activity of the specific pharmaceutically active agent; the age, body weight, general health, sex and diet of the patient; the time of administration; the rate of excretion; possible drug combinations; the severity of the particular condition being treated; and the form of administration.
- One of ordinary skill in the art would appreciate the variability of such factors and would be able to establish specific dose levels using no more than routine experimentation.
- Pharmacokinetic parameters such as bioavailability, absorption rate constant, apparent volume of distribution, unbound fraction, total clearance, fraction excreted unchanged, first-pass metabolism, elimination rate constant, half-life, and mean residence time are well known in the art.
- the optimal pharmaceutical formulations will be determined by one skilled in the art depending upon considerations such as the particular pharmaceutically active agent combination and the desired dosage. See, for example, "Remington 's Pharmaceutical Sciences", 18th ed. (1990, Mack Publishing Co., Easton, PA 18042), pp. 1435-1712, the disclosure of which is hereby incorporated by reference. Such formulations may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the essential lipids.
- the present pharmaceutical composition in accordance with the subject matter described herein may be an intravenous form or an oral dosage form, for example, a capsule, a tablet, liquid, and/or a powder packaged in, for example, a multi-use or single-use package, including for example, a container or bottle, a blister package.
- Single dosage kits and packages containing once per day, or once per treatment, amount of the pharmaceutical composition may be prepared.
- Single dose, unit dose, and once- daily disposable containers of the present pharmaceutical compositions are contemplated as within the scope of the present subject matter.
- the present pharmaceutical compositions may be used in combination with an additional pharmaceutical dosage form to enhance their effectiveness in treating a cancer, malignancy, or proliferative disorder.
- the present preferred compositions may be administered as part of a regimen additionally including any other pharmaceutical and/or pharmaceutical dosage form known in the art as effective for the treatment of a cancer, malignancy, or proliferative disorder.
- a pharmaceutically active ingredient other than those specified herein can be added to the present preferred compositions to enhance their effectiveness in treating a cancer, malignancy, or proliferative disorder. Accordingly, this additional pharmaceutically active ingredient or additional pharmaceutical dosage form can be administered to a patient either directly or indirectly, and concomitantly or sequentially, with the preferred compositions described herein.
- anti-cancer, anti-malignancy, or anti-proliferative disorder agents other than compounds discussed above are additionally contemplated as useful for combination therapy discussed herein.
- Combinations of any of the foregoing agents or their pharmaceutically acceptable salts or derivatives are contemplated herein.
- the present compositions and the additional pharmaceutical dosage form can be administered to a patient at the same time.
- one of the present preferred compositions and the additional pharmaceutical dosage form can be administered in the morning and the other can be administered in the evening.
- the presently described compounds can be administered to a patient in need thereof in multiple pharmaceutical dosage forms.
- This combination therapy may maximize the effectiveness of the present composition in treating a cancer, malignancy, or proliferative disorder.
- Analytical HPLC was performed on a Waters Autopurification system with PDA, MicroMass ZQ and ELSD detector. Analytical thin layer chromatography was performed on 250 ⁇ M silica gel F254 plates. Preparative thin layer chromatography was performed on 1000 ⁇ M silica gel F254 plates. Flash column chromatography was performed employing 230-400 mesh silica gel. Solvents were HPLC grade. All reagents were purchased from either Aldrich or Acros Organics and used without purification. All reactions were performed under argon protection.
- Synthetic Scheme 1 provides examples of synthesizing compounds 18-26, YK5
- Reagents and conditions (a) PMBCI, NaH, DMF, 0 0 C to it, 12 h, 95%; (b) NIS, MeCN, rt, 1 h, 98%; (c) 4,6- diamino-2-mercaptopyrimidine, neocuproine, CuI, K 2 CO 3 , DMSO, 120 0 C, 16 h, 65%; (d) Ac 2 O, DMAP, 110 0 C, 2 h, 91 %; (e) TFA, CHCI 3 , 62 0 C, 24 h, 95%; (f) HF/pyridine, NaNO 2 , 0 0 C, 1 h, 54%; (g) 1-methylpiperizine, DMF, 90 0C, 1 h, 90%; (h) NaOH, H 2 O, MeOH, 60 0 C, 1 h, 95 %; (i) acryloyl chloride, Et 3 N, dioxane, rt
- N-iodosuccinimide (4.13 g, 18.4 mmol) was added and stirred at rt for 1 h. Solvent was evaporated and the residue was purified by column chromatography (hexane:EtOAc, 4:1) to afford 6.3 g (98 %) of 20.
- Synthetic Scheme 2 provides examples of synthesizing compounds 28-36, YK30
- Reagents and conditions (a) NaH, EtOH, reflux, 12 h, 89%; (b) PMBCI, NaH, DMF, 0 0 C to rt, 12 h, 97%; (c) NIS, MeCN, rt, 1 h, 96%; (d) 4,6-diamino-2-mercaptopyrimidine, neocuproine, CuI, K 2 CO 3 , DMSO, 120 0 C, 16 h, 80%; (e) Ac 2 O, DMAP, 110 0 C, 2 h, 89%; (f) TFA, CHCI 3 , 62 0 C, 24 h, 92%; (g) HF/pyridine, NaNO 2 , 0 0 C, 1 h, 46%; (h) 1-methylpiperizine, DMF, 90 0 C, 1 h, 91%; (i) NaOH, H 2 O, MeOH, 60 0 C, 1 h, 93%; (j) acryl
- Synthetic Scheme 3 provides examples of synthesizing compounds 38-43, YK57
- Reagents and conditions (a) H(OCH 2 CH 2 ) 4 OH, DMF 80 0 C 3 h, ,83%; (b) HF/pyridine, NaNO 2 , 0 0 C, 42%; (c) 1- methylpiperazine, DMF, 90 0 C, 1 h, 91%; (d) NIS, CH 3 CN, rt, 1.5 h, ,85%; (e) 4,6-diamino-2- mercaptopyrimidine, neocuproine, CuI, K 3 PO 4 , DMSO, 150 0 C, 2.5 h, 73%; (f) acryloyl chloride, Et 3 N, CH 2 CI 2 , O 0C to rt, 8 h, 38%; (g) NaOH, H 2 O, THF, rt, 6 h, 52%; (h) D-biotin, DCC, DMAP, CH 2 CI 2 , sonicate, 8 h
- Synthetic Scheme 4 provides examples of synthesizing compounds 45-50, YK54
- Reagents and conditions (a) TsCI, NaOH, THF, H 2 O, O 0 C, 2 h, 78%; (b) piperazine, CH 3 CN, 75 0 C 12 h, 66%; (c) 24, DMF, 90 0 C, 2 h, 79%; (d) NaOH, MeOH, H 2 O, 60 0 C, 2 h, 98%; (e) acryloyl chloride, Et 3 N, CH 2 CI 2 , O 0 C, 7 h, 36%; (f) NaOH, THF, H 2 O, 3 h, 75%; (g) D-biotin, DCC, DMAP, CH 2 CI 2 , sonication, 13 h, 85%; (h) acryloyl chloride, Et 3 N, CH 2 CI 2 , O 0 C, 6 h, 41% [00308] (45) - 2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)e
- Reagents and conditions a. 1-Boc-piperazine, NaI, K 2 CO 3 , acetone, reflux, 22 h; b. CH 2 CI 2 :TFA (4:1), rt, 1 h; c. 24, K 2 CO 3 , 9O 0 C, 1.5 h; d. hydrazine hydrate, MeOH, rt, 2 h, then 1 M NaOH, 55°C, 2 h; e di-t-butyldicarbonate, Et 3 N, CH 2 CI 2 , rt, 20 h; f. acryloyl chloride, Et 3 N, CH 2 CI 2 , O 0 C, 2 h; g.
- N-(4-Bromobutyl)phthalimide (1.95 g, 6.89 mmol) and sodium iodide (81 mg, 0.537 mmol) were added to a suspension Of K 2 CO 3 (1.64 g, 11.88 mmol) and 1-Boc-piperazine (1.00 g, 5.37 mmol) in acetone (25 mL) and refluxed for 22 h.
- the reaction mixture was filtered and the solid was washed with acetone (3 x 50 mL).
- the filtrate was concentrated and the residue purified by column chromatography (hexane:EtOAc, 7:3 to 0:1) to afford 2.08 g (100%) of 58.
- Reagents and conditions a. CH 2 CI 2 :TFA (4:1 ), rt, 1 h; b. N-(2-(2-fluoro-4,6-dimethoxypyrimidin-5-ylthio)pyrimidin-4-yl)acetamide, K 2 CO 3 , 90°C, 1.5 h; c. hydrazine hydrate, MeOH, rt, 20 h, then 50°C, 3 h; d. di-t-butyldicarbonate, Et 3 N, CH 2 CI 2 , rt, 20 h; e. acryloyl chloride, Et 3 N, CH 2 CI 2 , O 0 C, 1.5 h; f. CH 2 CI 2 TFA (4:1 ), rt, 45 min.; g. Affi-Gel® 10 beads, DIEA, DMAP, DMF, 3 h.
- a solution of 64 ( ⁇ 0.122 mmol) in DMF (4 mL) was added to 6.8 mL (0.102 mmol) of Affi- Gel ® 10 beads (prewashed, 3 x 10 mL DMF) in a solid phase peptide synthesis vessel.
- 100 ⁇ L of N,N-diisopropylethylamine and several crystals of DMAP were added and this was shaken at rt for 3 h. Then the solvent was removed and the beads washed for 10 minutes each time with CH 2 Cl 2 (4 x 10 mL), DMF (4 x 10 mL), and j-PrOH (3 x 10 mL).
- the YK71 beads (65) were stored in z ' -PrOH at -80 0 C.
- Reagents and conditions a. potassium phthalimide, DMF, 110°C,18 h; b. p-tosyl chloride, Et 3 N, DMAP, CH 2 CI 2 , 5°C to rt, 24 h; c. 1-Boc-piperazine, K 2 CO 3 , dioxane, 80 0 C, 22 h; d. CH 2 CI 2 :TFA (4:1), rt, 1 h; e. 24, K 2 CO 3 , DMF, 90 0 C, 1.5 h; f. NH 2 NH 2 , MeOH, rt, 2 h then 1M NaOH (aq.), 50°C, 1.5 h; g. D-biotin, EDCI, DMAP, CH 2 CI 2 , sonicate, 2 h; h. acryloyl chloride, Et 3 N, CH 2 CI 2 , 0°C.
- TT-6 (72) N-(2-(2-(2-(2-(2-(4-(5-(4-acrylamido-6-ammopy ⁇ mi ⁇ iii-z-yimioj-'»,D- dimethoxypyrimidin-2-yl)piperazin-l-yl)ethoxy)ethoxy)ethyI)-5-(2-oxohexahydro- 1 H-thieno [3,4-d] imidazol-4-yl)pentanamide
- Reagents and conditions a. N-methylpiperazine, DMF, 90 0 C, 2.5 h; b. NIS, TFA, CH 3 CN, rt, 1.5 h; c. 3-aminobenzenethiol, neocuproine, CuI, K 3 PO 4 , DMF, 125 0 C, 17 h; d. RCOCI, Et 3 N; e. RCOOH, DCC, THF, rt; f. CH 2 CI 2 TFA (4:1), rt.
- YK139 (85) N-(3-(4,6-dimethoxy-2-(4-methylpiperazin-l-yl)pyrimidiii-5- ylthio)phenyl)cyclopropanecarboxamide
- TT-2 (87) N-(3-(4,6-dimethoxy-2-(4-methylpiperazin-l-yl)pyrimidin-5- ylthio)phenyl)cyclobutanecarboxamide
- TT-3 (88) N-(3-(4,6-dimethoxy-2-(4-methylpiperazm-l-yI)pyrimidin-5- ylthio)phenyl)cyclohexanecarboxamide
- Reagents and conditions a. PhB(OH) 2 , Na 2 CO 3 , Pd(OAc) 2 , PPh 3 , DME, 95°C, 15-20 h; b. N-methylpiperazine, DMF, 90°C, 1.5 h; c. NIS, TFA, CH 3 CN; d. 3-aminobenzenethiol, neocuproine, CuI, K 3 PO 4 , DMF, 120 0 C, 12 h; e. Boc-glycine, DCC, THF, rt, 12 h; f. CH 2 CI 2 )TFA (4:1), it
- Reagents and conditions a. benzyl alcohol, KOH, 18-crown-6, toluene, rt, 1 h; b. N-methylpiperazine, DMF, 80°C, 1.75 h; c. NIS, TFA, CH 3 CN, rt, 1 h; d. 3-aminobenzenethiol, neocuproine, CuI, K 2 CO 3 , DMF, 12O 0 C, 18 h; e. Ac 2 O, CH 2 CI 2 or PhCOCI, Et 3 N, CH 2 CI 2 ; f. RCOOH, DCC, THF, rt, 12 h; g. CH 2 CI 2 TFA (4:1), rt.
- TT-8 (101) N-(3-(4-(benzyloxy)-2-(4-methylpiperazm-l-yl)pyrimidin-5- ylthio)phenyl)benzamide
- TT-9 (102) 2-ammo-N-(3-(4-(beiizyloxy)-2-(4-methylpiperazin-l- yl)pyrimidin-5-ylthio)phenyl)acetamide
- 2,4-dichloropyrimidine (90) (2.0 g, 0.0134 mmol) in toluene (20 mL) was added p- methoxybenzyl alcohol (1.84 ml, 2.04 g, 0.0147 mol), KOH (0.825 g, 0.0147 mol) and 18- crown-6 (0.177 g, 0.00067 mol) and is stirred at rt for Ih.
- reaction mixture was diluted with EtOAc (350 mL), washed with water (2 x 50 mL), dried over MgSO 4 , filtered and concentrated to give an oil that was purified by column chromatography (hexane:CH 2 Cl 2 , 1:1 to 3:7) to afford 2.39 g (71%) of a mixture of 106 with the regioisomeric 4-chloro-2-(4- methoxybenzyloxy)pyrimidine (relative ratio 78:22 by 1 H-NMR, respectively).
- TT-12 (115) 2-amino-N-(3-(4-(cyclopentylmethoxy)-2-(4-methylpiperazin-l- yl)pyrimidin-5-ylthio)phenyl)acetamide
- TT-13 (116) 2-amino-N-(3-(2-(4-methyJpiperazin-l-yl)-4-phenoxypyrimidin-
- TT-14 (117) 2-amino-N-(3-(4-(cyclopentyloxy)-2-(4-methylpiperazin-l- yl)pyrimidin-5-ylthio)phenyl)acetamide
- TT-15 (118) 2-amino-N-(3-(4-(cyclohexyloxy)-2-(4-methylpiperazin-l- yI)pyrimidin-5-ylthio) phenyl)acetamide
- TT-16 (119) 2-amino-N-(3-(2-(4-methyIpiperazin-l-yl)-4-(pyridin-3- ylmethoxy)pyrimidin-5-ylthio) phenyl) acetamide
- Reagents and conditions a. Fmoc-glycine, DCC, THF, rt, 12 h; b. CH 2 CI 2 :piperidine (9:1), rt, 2h.
- TT-10 (121) 2-amino-N-(3-(4-(4-methoxybenzyloxy)-2-(4-methyIpiperazin-l- yl)pyrimidin-5-ylthio) phenyl)acetamide
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2012001993A MX353747B (en) | 2009-08-17 | 2010-08-17 | Heat shock protein binding compounds, compositions, and methods for making and using same. |
JP2012525652A JP2013502424A (en) | 2009-08-17 | 2010-08-17 | Heat shock protein binding compounds, compositions, and methods for making them |
AU2010284255A AU2010284255B2 (en) | 2009-08-17 | 2010-08-17 | Heat shock protein binding compounds, compositions, and methods for making and using same |
CN2010800368189A CN102753177A (en) | 2009-08-17 | 2010-08-17 | Heat shock protein binding compounds, compositions, and methods for making and using same |
EA201290062A EA201290062A1 (en) | 2009-08-17 | 2010-08-17 | COMPOUNDS, BINDING PROTEINS OF THERMAL SHOCK, COMPOSITIONS AND METHODS OF OBTAINING INDICATED COMPOUNDS |
BR112012003637A BR112012003637A2 (en) | 2009-08-17 | 2010-08-17 | "heat shock protein binding compounds, compositions, and methods for preparing and using them" |
EP10810519.8A EP2467142B1 (en) | 2009-08-17 | 2010-08-17 | 2-(Pyrimidin-5-yl)-thiopyrimidine derivatives as Hsp70 and Hsc70 modulators for the treatment of proliferative disorders |
NZ59826210A NZ598262A (en) | 2009-08-17 | 2010-08-17 | Heat shock protein binding compounds, compositions, and methods for making and using same |
CA2771190A CA2771190C (en) | 2009-08-17 | 2010-08-17 | Heat shock protein binding compounds, compositions, and methods for making and using same |
ES10810519.8T ES2608670T3 (en) | 2009-08-17 | 2010-08-17 | 2- (Pyrimidin-5-yl) -thiopyrimidine derivatives as modulators of Hsp70 and Hsc70 for the treatment of proliferative disorders |
KR1020127006838A KR101906146B1 (en) | 2009-08-17 | 2010-08-17 | Heat shock protein binding compounds, compositions, and methods for making and using same |
EP16189468.8A EP3205647B1 (en) | 2009-08-17 | 2010-08-17 | 2-(pyrimidin-5-yl)-thiopyrimidine derivatives as hsp70 and hsc70 modulators for the treatment of proliferative disorders |
US13/391,148 US9567318B2 (en) | 2009-08-17 | 2010-08-17 | Substituted pyrimidine compounds and uses thereof |
US15/230,700 US10052325B2 (en) | 2009-08-17 | 2016-08-08 | Heat shock protein binding compounds, compositions, and methods for making and using same |
US16/037,160 US10758538B2 (en) | 2009-08-17 | 2018-07-17 | Heat shock protein binding compounds, compositions, and methods for making and using same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27210109P | 2009-08-17 | 2009-08-17 | |
US61/272,101 | 2009-08-17 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/391,148 A-371-Of-International US9567318B2 (en) | 2009-08-17 | 2010-08-17 | Substituted pyrimidine compounds and uses thereof |
US15/230,700 Division US10052325B2 (en) | 2009-08-17 | 2016-08-08 | Heat shock protein binding compounds, compositions, and methods for making and using same |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2011022440A2 true WO2011022440A2 (en) | 2011-02-24 |
WO2011022440A3 WO2011022440A3 (en) | 2011-08-11 |
WO2011022440A9 WO2011022440A9 (en) | 2016-11-10 |
Family
ID=43607564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/045817 WO2011022440A2 (en) | 2009-08-17 | 2010-08-17 | Heat shock protein binding compounds, compositions, and methods for making and using same |
Country Status (13)
Country | Link |
---|---|
US (3) | US9567318B2 (en) |
EP (2) | EP2467142B1 (en) |
JP (3) | JP2013502424A (en) |
KR (1) | KR101906146B1 (en) |
CN (2) | CN108752280A (en) |
AU (1) | AU2010284255B2 (en) |
BR (1) | BR112012003637A2 (en) |
CA (1) | CA2771190C (en) |
EA (1) | EA201290062A1 (en) |
ES (2) | ES2817700T3 (en) |
MX (1) | MX353747B (en) |
NZ (3) | NZ598262A (en) |
WO (1) | WO2011022440A2 (en) |
Cited By (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012149493A3 (en) * | 2011-04-28 | 2014-05-08 | Sloan-Kettering Institute For Cancer Research | Hsp90 combination therapy |
US20140234858A1 (en) * | 2011-10-06 | 2014-08-21 | Whitehead Institute For Bio-Medical Research | Hsf1 as a marker in tumor prognosis and treatment |
WO2015036563A1 (en) | 2013-09-16 | 2015-03-19 | Bayer Pharma Aktiengesellschaft | Disubstituted trifluormethyl pyrimidinones and use thereof as ccr2 antagonists |
WO2015175707A1 (en) | 2014-05-13 | 2015-11-19 | Memorial Sloan Kettering Cancer Center | Hsp70 modulators and methods for making and using the same |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
WO2016113205A1 (en) | 2015-01-13 | 2016-07-21 | Bayer Pharma Aktiengesellschaft | Substituted pentafluoroethyl pyrimidinones and use thereof |
WO2016203405A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
WO2017062520A1 (en) | 2015-10-05 | 2017-04-13 | Memorial Sloan Kettering Cancer Center | Rational combination therapy for the treatment of cancer |
US9683003B2 (en) | 2014-07-01 | 2017-06-20 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme |
WO2017111076A1 (en) | 2015-12-24 | 2017-06-29 | 協和発酵キリン株式会社 | α, β UNSATURATED AMIDE COMPOUND |
US9695154B2 (en) | 2013-07-02 | 2017-07-04 | Millennium Pharmaceuticals, Inc. | Heteroaryl inhibitors of sumo activating enzyme |
US9834518B2 (en) | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
US9834571B2 (en) | 2012-05-05 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
WO2018013597A1 (en) * | 2016-07-12 | 2018-01-18 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
WO2018146469A1 (en) | 2017-02-07 | 2018-08-16 | Oblique Therapeutics Ab | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer |
US10052325B2 (en) | 2009-08-17 | 2018-08-21 | Memorial Sloan-Kettering Cancer Center | Heat shock protein binding compounds, compositions, and methods for making and using same |
US10077276B2 (en) | 2014-01-17 | 2018-09-18 | Novartis Ag | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 |
US10093646B2 (en) | 2014-01-17 | 2018-10-09 | Novartis Ag | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 |
WO2018235926A1 (en) | 2017-06-23 | 2018-12-27 | 協和発酵キリン株式会社 | α, β-UNSATURATED AMIDE COMPOUND |
WO2019051084A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
US10301278B2 (en) | 2014-01-17 | 2019-05-28 | Novartis Ag | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 |
WO2019177375A1 (en) * | 2018-03-13 | 2019-09-19 | 포로노이바이오 주식회사 | 2, 4, 5-substituted pyrimidine derivatives, method for preparing same, and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient |
WO2019182960A1 (en) * | 2018-03-21 | 2019-09-26 | Synblia Therapeutics, Inc. | Shp2 inhibitors and uses thereof |
WO2019199792A1 (en) | 2018-04-10 | 2019-10-17 | Revolution Medicines, Inc. | Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations |
US10617772B2 (en) | 2014-09-17 | 2020-04-14 | Memorial Sloan Kettering Cancer Center | Hsp9O-targeted inflammation and infection imaging and therapy |
WO2020076723A1 (en) | 2018-10-08 | 2020-04-16 | Revolution Medicines, Inc. | Shp2 inhibitor compositions for use in treating cancer |
US10647675B2 (en) | 2015-09-18 | 2020-05-12 | Kaken Pharmaceutical Co., Ltd. | Biaryl derivative and medicine containing same |
US10683293B2 (en) | 2014-08-04 | 2020-06-16 | Nuevolution A/S | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
WO2020180768A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
WO2020180770A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
US10858359B2 (en) | 2016-06-07 | 2020-12-08 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic ring derivatives useful as SHP2 inhibitors |
US10899710B2 (en) | 2015-08-07 | 2021-01-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pyridines and their use in the treatment of cancer |
US10934285B2 (en) | 2016-06-14 | 2021-03-02 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
US10988466B2 (en) | 2017-03-23 | 2021-04-27 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic derivatives useful as SHP2 inhibitors |
US11000536B2 (en) * | 2015-04-30 | 2021-05-11 | Nant Holdings Ip, Llc | Patient treatment via teratogenic pharmaceutical compounds |
US11001569B2 (en) | 2016-01-22 | 2021-05-11 | Janssen Pharmaceutica Nv | 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors |
WO2021092115A1 (en) | 2019-11-08 | 2021-05-14 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
WO2021091967A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
WO2021091982A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2021142026A1 (en) | 2020-01-07 | 2021-07-15 | Revolution Medicines, Inc. | Shp2 inhibitor dosing and methods of treating cancer |
US11136311B2 (en) | 2016-06-30 | 2021-10-05 | Janssen Pharmaceutica Nv | Heteroaromatic derivatives as NIK inhibitors |
US11180487B2 (en) | 2016-01-22 | 2021-11-23 | Janssen Pharmaceutica Nv | Substituted cyanoindoline derivatives as NIK inhibitors |
US11186589B2 (en) | 2016-06-30 | 2021-11-30 | Janssen Pharmaceutica Nv | Cyanoindoline derivatives as NIK inhibitors |
WO2022060196A1 (en) * | 2020-09-18 | 2022-03-24 | 보로노이바이오 주식회사 | Heteroaryl derivative, method for preparation thereof, and pharmaceutical composition comprising same as active ingredient |
US11364300B2 (en) | 2018-05-01 | 2022-06-21 | Revolution Medicines, Inc. | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors |
WO2022140427A1 (en) | 2020-12-22 | 2022-06-30 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
US11414389B2 (en) | 2020-05-08 | 2022-08-16 | Eli Lilly And Company | (trifluoromethyl)pyrimidine-2-amine compounds |
US11447479B2 (en) | 2019-12-20 | 2022-09-20 | Nuevolution A/S | Compounds active towards nuclear receptors |
US11466000B2 (en) | 2019-03-19 | 2022-10-11 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
US11613532B2 (en) | 2020-03-31 | 2023-03-28 | Nuevolution A/S | Compounds active towards nuclear receptors |
US11673896B2 (en) | 2017-01-23 | 2023-06-13 | Revolution Medicines, Inc. | Pyridine compounds as allosteric SHP2 inhibitors |
US11673901B2 (en) | 2017-12-15 | 2023-06-13 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric SHP2 inhibitors |
US11685749B2 (en) | 2018-05-01 | 2023-06-27 | Revolution Medicines, Inc. | C26-linked rapamycin analogs as mTOR inhibitors |
US11702411B2 (en) | 2017-10-12 | 2023-07-18 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors |
US11739093B2 (en) | 2017-01-23 | 2023-08-29 | Revolution Medicines, Inc. | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors |
US11780843B2 (en) | 2020-03-31 | 2023-10-10 | Nuevolution A/S | Compounds active towards nuclear receptors |
US12053470B2 (en) | 2017-01-10 | 2024-08-06 | Novartis Ag | Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2645689T3 (en) | 2008-05-21 | 2017-12-07 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
CN109374889B (en) * | 2011-07-08 | 2022-04-19 | 索隆-基特林癌症研究协会 | Use of labeled HSP90 inhibitors |
EP3052190A4 (en) * | 2013-10-01 | 2017-07-19 | New York University | Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof |
PE20211544A1 (en) | 2014-01-16 | 2021-08-16 | Fmc Corp | PYRIMIDINYLOXY BENZENE DERIVATIVES AS HERBICIDES |
US11006631B2 (en) | 2015-03-18 | 2021-05-18 | Fmc Corporation | Substituted pyrimidinyloxy pyridine derivatives as herbicides |
TW202400564A (en) | 2015-06-05 | 2024-01-01 | 美商艾佛艾姆希公司 | Pyrimidinyloxy benzene derivatives as herbicides |
WO2017011288A1 (en) | 2015-07-13 | 2017-01-19 | E I Du Pont De Nemours And Company | Aryloxypyrimidinyl ethers as herbicides |
WO2017160569A1 (en) * | 2016-03-14 | 2017-09-21 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
WO2018118015A1 (en) | 2016-12-19 | 2018-06-28 | Morehouse School Of Medicine | Compositions and methods for treating diseases by inhibiting exosome release |
JP2020506244A (en) | 2017-02-07 | 2020-02-27 | オブリーク セラピューティクス アーベー | Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer |
CA3051644A1 (en) | 2017-02-07 | 2018-08-16 | Oblique Therapeutics Ab | Sulfinylpyridines and their use in the treatment of cancer |
MX2019009266A (en) | 2017-02-07 | 2019-11-05 | Oblique Therapeutics Ab | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer. |
KR102007135B1 (en) | 2017-03-20 | 2019-08-02 | 포르마 세라퓨틱스 인크. | Pyrrolopyrrole Composition As Pyruvate Kinase (PKR) Activator |
WO2018204164A1 (en) | 2017-05-02 | 2018-11-08 | Fmc Corporation | Pyrimidinyloxy benzo-fused compounds as herbicides |
US11801284B2 (en) | 2017-12-13 | 2023-10-31 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating motor neuron diseases |
CN112424188A (en) * | 2018-04-30 | 2021-02-26 | 里邦医疗公司 | Pyridazinones as PARP7 inhibitors |
JP7450610B2 (en) | 2018-09-19 | 2024-03-15 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | Activation of pyruvate kinase R |
CN113166060B (en) | 2018-09-19 | 2024-01-09 | 诺沃挪第克健康护理股份公司 | Treatment of sickle cell disease with pyruvate kinase-activating compounds |
CA3145864A1 (en) | 2019-07-03 | 2021-01-07 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof |
CA3159188A1 (en) | 2019-10-30 | 2021-05-06 | Ribon Therapeutics, Inc. | Pyridazinones as parp7 inhibitors |
CN110702483B (en) * | 2019-11-07 | 2022-05-10 | 上海海洋大学 | Pretreatment method for identifying seafood or meat at ultra-fast speed |
CN110804028B (en) * | 2019-11-14 | 2020-07-31 | 中山万远新药研发有限公司 | Piperazinyl substituted diaryl sulfoxide compound and composition and application thereof |
CN112487680B (en) * | 2020-11-27 | 2024-05-03 | 西安空间无线电技术研究所 | Method for evaluating and regulating ion trap non-harmonic potential |
EP4306647A1 (en) * | 2021-03-10 | 2024-01-17 | Sumitomo Pharma Co., Ltd. | Method for producing fusion protein |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB951431A (en) * | 1959-03-17 | 1964-03-04 | Wellcome Found | Pyrimidine derivatives and the manufacture thereof |
GB990857A (en) | 1961-10-13 | 1965-05-05 | Wellcome Found | 1,3-diazaphenothiazines |
US3248393A (en) | 1960-06-23 | 1966-04-26 | Burroughs Wellcome Co | 1, 3-diazaphenothiazines and method |
CH605828A5 (en) | 1974-12-24 | 1978-10-13 | Hoffmann La Roche | |
US4039543A (en) | 1974-12-24 | 1977-08-02 | Hoffmann-La Roche Inc. | Benzylpyrimidines |
US4096264A (en) | 1975-12-09 | 1978-06-20 | Merck & Co., Inc. | Certain substituted imidazo [1,2-a] pyridines |
DE3311703A1 (en) * | 1983-03-30 | 1984-10-04 | Bayer Ag, 5090 Leverkusen | UREA DERIVATIVES |
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
FR2588189B1 (en) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION |
ATE141502T1 (en) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | USE OF CARRAGEENAN IN TOPICAL OPHTHALMOLOGICAL COMPOSITIONS |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
NZ274978A (en) * | 1993-10-12 | 1998-04-27 | Du Pont Merck Pharma | 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof |
DE4423098A1 (en) * | 1994-07-01 | 1996-01-04 | Hoechst Ag | Use of conjugated compounds containing pyrimidine groups as electroluminescent materials |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
JPH09236070A (en) | 1996-02-29 | 1997-09-09 | Denso Corp | Starter |
US5707930A (en) * | 1996-09-16 | 1998-01-13 | Zeneca Limited | 4-cycloalkyl-5-substituted pyrimidine compounds useful as crop protection agents |
EP1165522A1 (en) | 1999-04-06 | 2002-01-02 | Krenitsky Pharmaceuticals, Inc. | Neurotrophic thio substituted pyrimidines |
DE60136731D1 (en) | 2000-09-20 | 2009-01-08 | Ortho Mcneil Pharm Inc | PYRAZINE DERIVATIVES THAN TYROSINE KINASE MODULATORS |
MXPA03004780A (en) | 2000-12-18 | 2004-05-21 | Actelion Pharmaceuticals Ltd | Novel sulfamides and their use as endothelin receptor antagonists. |
US6423720B1 (en) | 2001-02-01 | 2002-07-23 | Duquesne University Of The Holy Ghost | Pyrimidine compounds and methods for making and using the same |
US7501429B2 (en) * | 2001-04-11 | 2009-03-10 | Queen's University At Kingston | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents |
WO2003055860A1 (en) | 2001-12-21 | 2003-07-10 | Vernalis (Cambridge) Limited | 3,4-diarylpyrazoles and their use in the therapy of cancer |
EP1534286B1 (en) | 2002-07-29 | 2009-12-09 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
AU2004220234C1 (en) | 2003-02-13 | 2013-01-17 | Msd K.K. | Novel 2-pyridinecarboxamide derivatives |
NZ546044A (en) * | 2003-08-29 | 2009-09-25 | Vernalis Cambridge Ltd | Pyrimidothiophene compounds |
US20050070712A1 (en) * | 2003-09-26 | 2005-03-31 | Christi Kosogof | Pyrimidine derivatives as ghrelin receptor modulators |
JP4717876B2 (en) | 2004-03-05 | 2011-07-06 | エフ.ホフマン−ラ ロシュ アーゲー | Diaminopyrimidines as P2X3 and P2X2 / 3 antagonists |
JP4906715B2 (en) * | 2004-05-08 | 2012-03-28 | ニューロジェン・コーポレーション | 4,5-disubstituted-2-arylpyrimidines |
CA2600531A1 (en) * | 2005-03-16 | 2006-09-28 | Targegen, Inc. | Pyrimidine compounds and methods of use |
CA2620129C (en) | 2005-09-01 | 2014-12-23 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
WO2007131034A1 (en) | 2006-05-03 | 2007-11-15 | The Regents Of The University Of Michigan | Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70 |
JP2008081492A (en) * | 2006-08-31 | 2008-04-10 | Banyu Pharmaceut Co Ltd | New aminopyridine derivative having aurora a selective inhibitory action |
US20080124407A1 (en) | 2006-10-10 | 2008-05-29 | University Of Washington | Inhibiting cyp3a4 induction |
AU2007333394C1 (en) | 2006-12-08 | 2011-08-18 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
US8846704B2 (en) | 2007-01-31 | 2014-09-30 | YM Biosciences Austraila Pty Ltd | Thiopyrimidine-based compounds and uses thereof |
WO2008153042A1 (en) * | 2007-06-11 | 2008-12-18 | Kyowa Hakko Kirin Co., Ltd. | Anti-tumor agent |
WO2009023846A2 (en) * | 2007-08-15 | 2009-02-19 | The Research Foundation Of State University Of New York | Methods for heat shock protein dependent cancer treatment |
WO2009061345A2 (en) | 2007-11-07 | 2009-05-14 | Cornell Research Foundation, Inc. | Targeting cdk4 and cdk6 in cancer therapy |
PE20091236A1 (en) * | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | PYRIMIDINE DERIVATIVES AS IMMUNOMODULATORS OF TLR7 |
WO2010144345A1 (en) | 2009-06-08 | 2010-12-16 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
EP2467142B1 (en) | 2009-08-17 | 2016-09-21 | Memorial Sloan-Kettering Cancer Center | 2-(Pyrimidin-5-yl)-thiopyrimidine derivatives as Hsp70 and Hsc70 modulators for the treatment of proliferative disorders |
US20150291565A1 (en) | 2012-11-13 | 2015-10-15 | Memorial Sloan-Kettering Cancer Center | Indole compounds and their use as antimicrobials |
ES2774975T3 (en) | 2014-05-13 | 2020-07-23 | Memorial Sloan Kettering Cancer Center | Hsp70 modulators and methods of making and using it |
US10308660B2 (en) | 2015-06-19 | 2019-06-04 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
AU2016324483B2 (en) | 2015-09-18 | 2021-07-29 | Memorial Sloan Kettering Cancer Center | Methods and compositions of inhibiting DCN1-UBC12 interaction |
-
2010
- 2010-08-17 EP EP10810519.8A patent/EP2467142B1/en active Active
- 2010-08-17 JP JP2012525652A patent/JP2013502424A/en not_active Ceased
- 2010-08-17 CN CN201810695781.9A patent/CN108752280A/en active Pending
- 2010-08-17 NZ NZ59826210A patent/NZ598262A/en not_active IP Right Cessation
- 2010-08-17 KR KR1020127006838A patent/KR101906146B1/en active IP Right Grant
- 2010-08-17 BR BR112012003637A patent/BR112012003637A2/en not_active IP Right Cessation
- 2010-08-17 ES ES16189468T patent/ES2817700T3/en active Active
- 2010-08-17 NZ NZ623069A patent/NZ623069A/en not_active IP Right Cessation
- 2010-08-17 MX MX2012001993A patent/MX353747B/en active IP Right Grant
- 2010-08-17 CA CA2771190A patent/CA2771190C/en not_active Expired - Fee Related
- 2010-08-17 ES ES10810519.8T patent/ES2608670T3/en active Active
- 2010-08-17 US US13/391,148 patent/US9567318B2/en active Active
- 2010-08-17 CN CN2010800368189A patent/CN102753177A/en active Pending
- 2010-08-17 EP EP16189468.8A patent/EP3205647B1/en active Active
- 2010-08-17 NZ NZ713361A patent/NZ713361A/en not_active IP Right Cessation
- 2010-08-17 WO PCT/US2010/045817 patent/WO2011022440A2/en active Application Filing
- 2010-08-17 AU AU2010284255A patent/AU2010284255B2/en not_active Ceased
- 2010-08-17 EA EA201290062A patent/EA201290062A1/en unknown
-
2015
- 2015-08-17 JP JP2015160345A patent/JP6465774B2/en active Active
-
2016
- 2016-08-08 US US15/230,700 patent/US10052325B2/en active Active
-
2018
- 2018-07-17 US US16/037,160 patent/US10758538B2/en active Active
- 2018-08-27 JP JP2018158360A patent/JP2018188476A/en not_active Withdrawn
Non-Patent Citations (2)
Title |
---|
None |
See also references of EP2467142A4 |
Cited By (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
US10758538B2 (en) | 2009-08-17 | 2020-09-01 | Memorial Sloan-Kettering Cancer Center | Heat shock protein binding compounds, compositions, and methods for making and using same |
US10052325B2 (en) | 2009-08-17 | 2018-08-21 | Memorial Sloan-Kettering Cancer Center | Heat shock protein binding compounds, compositions, and methods for making and using same |
JP2014523516A (en) * | 2011-04-28 | 2014-09-11 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | HSP90 combination therapy |
KR102027448B1 (en) | 2011-04-28 | 2019-10-01 | 슬로안-케테링인스티튜트퍼캔서리서치 | Hsp90 combination therapy |
KR20140059757A (en) * | 2011-04-28 | 2014-05-16 | 슬로안-케테링인스티튜트퍼캔서리서치 | Hsp90 combination therapy |
WO2012149493A3 (en) * | 2011-04-28 | 2014-05-08 | Sloan-Kettering Institute For Cancer Research | Hsp90 combination therapy |
US9834518B2 (en) | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
US9696313B2 (en) * | 2011-10-06 | 2017-07-04 | Whitehead Institute For Biomedical Research | HSF1 as a marker in tumor prognosis and treatment |
US20140234858A1 (en) * | 2011-10-06 | 2014-08-21 | Whitehead Institute For Bio-Medical Research | Hsf1 as a marker in tumor prognosis and treatment |
US9834571B2 (en) | 2012-05-05 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
US9695154B2 (en) | 2013-07-02 | 2017-07-04 | Millennium Pharmaceuticals, Inc. | Heteroaryl inhibitors of sumo activating enzyme |
WO2015036563A1 (en) | 2013-09-16 | 2015-03-19 | Bayer Pharma Aktiengesellschaft | Disubstituted trifluormethyl pyrimidinones and use thereof as ccr2 antagonists |
US11952386B2 (en) | 2014-01-17 | 2024-04-09 | Novartis Ag | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 |
US10093646B2 (en) | 2014-01-17 | 2018-10-09 | Novartis Ag | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 |
US10968235B2 (en) | 2014-01-17 | 2021-04-06 | Novartis Ag | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 |
US10301278B2 (en) | 2014-01-17 | 2019-05-28 | Novartis Ag | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 |
US10774065B2 (en) | 2014-01-17 | 2020-09-15 | Novartis Ag | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 |
US10077276B2 (en) | 2014-01-17 | 2018-09-18 | Novartis Ag | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 |
US11401259B2 (en) | 2014-01-17 | 2022-08-02 | Novartis Ag | 1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 |
US10336774B2 (en) | 2014-01-17 | 2019-07-02 | Novartis Ag | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 |
US10647683B2 (en) | 2014-05-13 | 2020-05-12 | Memorial Sloan Kettering Cancer Center | Hsp70 modulators and methods for making and using the same |
US9878987B2 (en) | 2014-05-13 | 2018-01-30 | Memorial Sloan Kettering Cancer Center | HSP70 modulators and methods for making and using the same |
CN107074806A (en) * | 2014-05-13 | 2017-08-18 | 纪念斯隆-凯特琳癌症中心 | HSP70 regulators with and production and preparation method thereof |
US10160729B2 (en) | 2014-05-13 | 2018-12-25 | Memorial Sloan Kettering Cancer Center | Hsp70 modulators and methods for making and using the same |
WO2015175707A1 (en) | 2014-05-13 | 2015-11-19 | Memorial Sloan Kettering Cancer Center | Hsp70 modulators and methods for making and using the same |
AU2015259173B2 (en) * | 2014-05-13 | 2019-09-05 | Memorial Sloan Kettering Cancer Center | Hsp70 modulators and methods for making and using the same |
CN107074806B (en) * | 2014-05-13 | 2021-04-23 | 纪念斯隆-凯特琳癌症中心 | HSP70 modulators and methods of making and using the same |
US10780090B2 (en) | 2014-07-01 | 2020-09-22 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme |
US9683003B2 (en) | 2014-07-01 | 2017-06-20 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme |
US9962386B2 (en) | 2014-07-01 | 2018-05-08 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme |
US10335410B2 (en) | 2014-07-01 | 2019-07-02 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
US10683293B2 (en) | 2014-08-04 | 2020-06-16 | Nuevolution A/S | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
US11254681B2 (en) | 2014-08-04 | 2022-02-22 | Nuevolution A/S | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
US10689383B2 (en) | 2014-08-04 | 2020-06-23 | Nuevolution A/S | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
US10617772B2 (en) | 2014-09-17 | 2020-04-14 | Memorial Sloan Kettering Cancer Center | Hsp9O-targeted inflammation and infection imaging and therapy |
US11065350B2 (en) | 2014-09-17 | 2021-07-20 | Memorial Sloan Kettering Cancer Center | HSP90-targeted inflammation and infection imaging and therapy |
WO2016113205A1 (en) | 2015-01-13 | 2016-07-21 | Bayer Pharma Aktiengesellschaft | Substituted pentafluoroethyl pyrimidinones and use thereof |
US11000536B2 (en) * | 2015-04-30 | 2021-05-11 | Nant Holdings Ip, Llc | Patient treatment via teratogenic pharmaceutical compounds |
US12016872B2 (en) | 2015-04-30 | 2024-06-25 | Nant Holdings Ip, Llc | Patient treatment via teratogenic pharmaceutical compounds |
WO2016203405A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
US10899710B2 (en) | 2015-08-07 | 2021-01-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pyridines and their use in the treatment of cancer |
US10647675B2 (en) | 2015-09-18 | 2020-05-12 | Kaken Pharmaceutical Co., Ltd. | Biaryl derivative and medicine containing same |
WO2017062520A1 (en) | 2015-10-05 | 2017-04-13 | Memorial Sloan Kettering Cancer Center | Rational combination therapy for the treatment of cancer |
AU2021204307B2 (en) * | 2015-12-24 | 2023-06-01 | Kyowa Kirin Co., Ltd. | a, ß unsaturated amide compound |
WO2017111076A1 (en) | 2015-12-24 | 2017-06-29 | 協和発酵キリン株式会社 | α, β UNSATURATED AMIDE COMPOUND |
US11001569B2 (en) | 2016-01-22 | 2021-05-11 | Janssen Pharmaceutica Nv | 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors |
US11180487B2 (en) | 2016-01-22 | 2021-11-23 | Janssen Pharmaceutica Nv | Substituted cyanoindoline derivatives as NIK inhibitors |
US10858359B2 (en) | 2016-06-07 | 2020-12-08 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic ring derivatives useful as SHP2 inhibitors |
US11905283B2 (en) | 2016-06-14 | 2024-02-20 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
US10934285B2 (en) | 2016-06-14 | 2021-03-02 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
US11186589B2 (en) | 2016-06-30 | 2021-11-30 | Janssen Pharmaceutica Nv | Cyanoindoline derivatives as NIK inhibitors |
US11136311B2 (en) | 2016-06-30 | 2021-10-05 | Janssen Pharmaceutica Nv | Heteroaromatic derivatives as NIK inhibitors |
CN109983001A (en) * | 2016-07-12 | 2019-07-05 | 锐新医药公司 | Tri- substituted type 3- methylpyrazine of the disubstituted type 3- methylpyrazine of 2,5- and 2,5,6- as allosteric SHP2 inhibitor |
US10590090B2 (en) | 2016-07-12 | 2020-03-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors |
US11661401B2 (en) | 2016-07-12 | 2023-05-30 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors |
CN109983001B (en) * | 2016-07-12 | 2023-04-04 | 锐新医药公司 | 2, 5-disubstituted 3-methylpyrazines and 2,5, 6-trisubstituted 3-methylpyrazines as allosteric SHP2 inhibitors |
IL264186B2 (en) * | 2016-07-12 | 2024-08-01 | Revolution Medicines Inc | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
EP3484856B1 (en) * | 2016-07-12 | 2023-11-15 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
EP4302834A3 (en) * | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
WO2018013597A1 (en) * | 2016-07-12 | 2018-01-18 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
IL264186B1 (en) * | 2016-07-12 | 2024-04-01 | Revolution Medicines Inc | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
US12053470B2 (en) | 2017-01-10 | 2024-08-06 | Novartis Ag | Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor |
US11739093B2 (en) | 2017-01-23 | 2023-08-29 | Revolution Medicines, Inc. | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors |
US11673896B2 (en) | 2017-01-23 | 2023-06-13 | Revolution Medicines, Inc. | Pyridine compounds as allosteric SHP2 inhibitors |
WO2018146469A1 (en) | 2017-02-07 | 2018-08-16 | Oblique Therapeutics Ab | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer |
US10988466B2 (en) | 2017-03-23 | 2021-04-27 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic derivatives useful as SHP2 inhibitors |
WO2018235926A1 (en) | 2017-06-23 | 2018-12-27 | 協和発酵キリン株式会社 | α, β-UNSATURATED AMIDE COMPOUND |
KR20200019979A (en) | 2017-06-23 | 2020-02-25 | 쿄와 기린 가부시키가이샤 | α, β unsaturated amide compounds |
WO2019051084A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
US11596633B2 (en) | 2017-09-07 | 2023-03-07 | Revolution Medicines, Inc. | SHP2 inhibitor compositions and methods for treating cancer |
US11702411B2 (en) | 2017-10-12 | 2023-07-18 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors |
US11673901B2 (en) | 2017-12-15 | 2023-06-13 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric SHP2 inhibitors |
WO2019177375A1 (en) * | 2018-03-13 | 2019-09-19 | 포로노이바이오 주식회사 | 2, 4, 5-substituted pyrimidine derivatives, method for preparing same, and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient |
WO2019182960A1 (en) * | 2018-03-21 | 2019-09-26 | Synblia Therapeutics, Inc. | Shp2 inhibitors and uses thereof |
WO2019199792A1 (en) | 2018-04-10 | 2019-10-17 | Revolution Medicines, Inc. | Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations |
US11364300B2 (en) | 2018-05-01 | 2022-06-21 | Revolution Medicines, Inc. | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors |
US12048749B2 (en) | 2018-05-01 | 2024-07-30 | Revolution Medicines, Inc. | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors |
US11685749B2 (en) | 2018-05-01 | 2023-06-27 | Revolution Medicines, Inc. | C26-linked rapamycin analogs as mTOR inhibitors |
WO2020076723A1 (en) | 2018-10-08 | 2020-04-16 | Revolution Medicines, Inc. | Shp2 inhibitor compositions for use in treating cancer |
WO2020180768A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
WO2020180770A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
US11466000B2 (en) | 2019-03-19 | 2022-10-11 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
WO2021091967A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
WO2021091982A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
WO2021092115A1 (en) | 2019-11-08 | 2021-05-14 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
US11447479B2 (en) | 2019-12-20 | 2022-09-20 | Nuevolution A/S | Compounds active towards nuclear receptors |
WO2021142026A1 (en) | 2020-01-07 | 2021-07-15 | Revolution Medicines, Inc. | Shp2 inhibitor dosing and methods of treating cancer |
US11613532B2 (en) | 2020-03-31 | 2023-03-28 | Nuevolution A/S | Compounds active towards nuclear receptors |
US11780843B2 (en) | 2020-03-31 | 2023-10-10 | Nuevolution A/S | Compounds active towards nuclear receptors |
US11414389B2 (en) | 2020-05-08 | 2022-08-16 | Eli Lilly And Company | (trifluoromethyl)pyrimidine-2-amine compounds |
US11773067B2 (en) | 2020-05-08 | 2023-10-03 | Eli Lilly And Company | (Trifluoromethyl)pyrimidine-2-amine compounds |
WO2022060196A1 (en) * | 2020-09-18 | 2022-03-24 | 보로노이바이오 주식회사 | Heteroaryl derivative, method for preparation thereof, and pharmaceutical composition comprising same as active ingredient |
WO2022140427A1 (en) | 2020-12-22 | 2022-06-30 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2010284255B2 (en) | Heat shock protein binding compounds, compositions, and methods for making and using same | |
KR101446742B1 (en) | N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidine-2,4-diamine derivatives or pharmaceutically acceptable salt thereof, and pharmaceutical composition for the prevention or treatment of cancer containing the same as an active ingredient | |
US7465718B2 (en) | Ansamycins having improved pharmacological and biological properties | |
AU765151B2 (en) | Pyrimidine compounds | |
ES2647416T3 (en) | Selective delta PI3K inhibitors | |
KR101335917B1 (en) | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidine compound and their uses | |
IL151392A (en) | 4 - amino - 5 - cyano - 2 - anilino - pyrimidine derivatives and their use as inhibitors of cell-cycle kinases | |
US20210261554A1 (en) | Ripk2 inhibitors and method of treating cancer with same | |
Zhan et al. | Discovery of pyrazole-thiophene derivatives as highly Potent, orally active Akt inhibitors | |
US20090093494A1 (en) | 4-Pyrimidineamine Compounds And Uses As Anti-Proliferative Agents | |
Tapera et al. | Design, synthesis, molecular docking and biological evaluation of 1, 2, 4-triazole derivatives possessing a hydrazone moiety as anti-breast cancer agents | |
Wang et al. | Discovery of 2H-benzo [b][1, 4] oxazin-3 (4H)-one derivatives as potent and selective CDK9 inhibitors that enable transient target engagement for the treatment of hematologic malignancies | |
Wang et al. | Design, synthesis, and biological evaluation of 2-Anilino-4-Triazolpyrimidine derivatives as CDK4/HDACs inhibitors | |
Li et al. | Design, synthesis and biological assessment of novel CDK4 inhibitor with potent anticancer activity | |
Wang et al. | Design, synthesis and anti-tumor efficacy of novel phenyl thiazole/triazole derivatives as selective TrkA inhibitors | |
Lee et al. | Discovery of N-benzylbenzamide-based allosteric inhibitors of Aurora kinase A |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080036818.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10810519 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2771190 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010284255 Country of ref document: AU Ref document number: MX/A/2012/001993 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012525652 Country of ref document: JP Ref document number: 201290062 Country of ref document: EA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2010284255 Country of ref document: AU Date of ref document: 20100817 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2010810519 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010810519 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2281/CHENP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20127006838 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13391148 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012003637 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012003637 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120217 |